EP0970110A1 - 87 humane sekretierte proteine - Google Patents
87 humane sekretierte proteineInfo
- Publication number
- EP0970110A1 EP0970110A1 EP98911772A EP98911772A EP0970110A1 EP 0970110 A1 EP0970110 A1 EP 0970110A1 EP 98911772 A EP98911772 A EP 98911772A EP 98911772 A EP98911772 A EP 98911772A EP 0970110 A1 EP0970110 A1 EP 0970110A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- gene
- tissue
- seq
- polypeptides
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Definitions
- This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.
- sorting signals are amino acid motifs located within the protein, to target proteins to particular cellular organelles.
- One type of sorting signal directs a class of proteins to an organelle called the endoplasmic reticulum (ER).
- ER endoplasmic reticulum
- the ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus.
- the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles. Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein.
- vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.
- the present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.
- isolated refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state.
- an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.
- a "secreted” protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.
- a "polynucleotide” refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC.
- the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence.
- a "polypeptide” refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.
- the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis).
- a representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number.
- the ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA.
- the ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.
- a “polynucleotide” of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC.
- Stringent hybridization conditions refers to an overnight incubation at 42°
- nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature.
- washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).
- blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations.
- the inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.
- polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).
- the polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double- stranded regions.
- the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- a polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons.
- Modified bases include, for example, tritylated bases and unusual bases such as inosine.
- polynucleotide embraces chemically, enzymatically, or metabolically modified forms.
- the polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids.
- the polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl teraiini.
- polypeptides may be branched , for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.
- Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance,
- SEQ ID NO:X refers to a polynucleotide sequence while “SEQ ID NO:Y” refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.
- a polypeptide having biological activity refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)
- polypeptide fragments comprise the amino acid sequence:
- DPEAADSGEPQNKRTPDLPEEEYVKEEIQENEEAVKKMLVEATREFEEV DES (SEQ ID NO:239); QKLKRKAEEDPEAADSGEPQNKRTPDLPEEEYVKEEIQENEE AVKKMLVEATREFEEWVDES (SEQ ID NO:240); KAMEKSSLTQHSWQSLKDR YLKHLRGQEHKYLLGDAPVSPSSQKLKRKAEEDPEAADSGEPQNKRTPDLPEE EYVKEEIQENEEAVKKMLVEATREFEEVWDESPPDFEIHI (SEQ ID NO:241). Also preferred are the polynucleotide fragments encoding these polypeptide fragments. This gene maps to chromosome 16, and therefore can be used as a marker in linkage analysis for chromosome 16.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cell-cell interaction or cell-matrix interaction.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the brain and kidney
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., brain and other tissue of the nervous system, and kidney, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution and homology to nucleolin indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases involving cell-cell interaction or cell-extracellular matrix interaction.
- the translation product of this gene shares sequence homology with a porcine zona pellucida protein ZPDS.1711. (See Accession No. R39356.) These two proteins have weak homology with Drosophila commissureless and metal homeostasis proteins which are thought to be important in controlling growth cone guidance across the CNS midline and protecting cells against reactive oxygen toxicity. thus, based on homology, it is likely that this gene also be involved in development.
- Preferred polypeptide fragments comprise the amino acid sequence: LPSYDEAERTKAEATIPLVPGRDEDF VGRDDFDDADQL GNDGjTMLTFFMAFLFNWIGFFLSFCLTTSAAGRYGAISG FGLSLIKWILIVRFSTYFPGYFDGQYWLWWVFLVLGFLLFLRGFINYAKVRKM PETFSNLPRTRVLFI (SEQ ID NO:242); and/or AGRYGAISGFGLSLIKWTLIVRFS (SEQ ID NO:243). Also preferred are polynucleotide fragments encoding these polypeptide fragments. This gene maps to chromosome 5, and therefore can be used in linkage analysis as a marker for chromosome 5. This gene is expressed primarily in kidney, adrenal gland, brain and to a lesser extent in wide range of tissues.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, fertilization control or tissue damages by metabolites or other toxic agents.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the reproductive and urosecretion system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., kidney, adrenal gland, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., kidney, adrenal gland, and brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- the tissue distribution and homology to zona pellucida protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for fertility control such as contraceptive development.
- the homology with metal homeostasis and commissureless genes indicates the gene's function in spermatozoa guidance and protection. It would also be useful for the treatment/diagnosis of tissue damages caused by toxic metabolites and other agents since the gene product is also expressed in urosecretive tissues.
- polypeptide fragments comprise the amino acid sequence: MKHLSAWNFT KLTFLQLWEI FEGSVENCQTLTSYSKLQIKYTFSRGSTFYI (SEQ ID NO:244). Also preferred are polynucleotide fragments encoding these polypeptide fragments. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, digestive and nutrient transport utilization disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue(s) or cell type(s) e.g., hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma,
- tissue distribution in liver and placenta indicates that the protein product is either an extracellular enzyme or a molecule carrier. Therefore, polynucleotides and polypeptides corresponding to this gene are useful for diagnosis/treatment of digestive and nutrient transport/utilization disorders, including malabsorption and malnutrition.
- This gene shares homology with the sap47 gene of Drosophila melanogaster, a gene which codes for a conserved neuronal protein associated with synaptic terminals. (See Mol. Brain Res. 32:45-54 (1995); see also, Accession No. 929571.) Thus, based on homology, the gene of the present invention also should be associated with synaptic terminals.
- Preferred polypeptide fragments comprise the amino acid sequence: FSSDFRTSPWESRRVESKATSARCGLWGSGPRRRPASGMFRGLSSWLGLQQP VAGGGQPNGDAPPEQPSETVAESAEEELQQAGDQELLHQAKDFGNYLFNFASA ATKKITESVAETAQTIKKSVEEGKIDGIIDKTIIGDFQKEQK-KFVEEQHTKKSEA AVPPWVDTNDEETIQQQILALSADKRNFLRDPPAGVQFNF ⁇ FDQMYPVALVML (SEQ ID NO:245); MRFALVPKLVKEEVFWRNYFYRVSLIKQSAQLTALAAQQQA AGKGGEEQ (SEQ ID NO:246); STSPGVSEFVSDAFDACNLNQEDLRKEMEQL VLDKXQEETAVLEEDSADWEKELQQELQEYEVVTESEKRDENWDK (SEQ ID NO:247); SPWESRRVESKATSARCGLWGSGPRRRPASGMFR
- This gene is expressed primarily in kidney pyramids and to a lesser extent in lung and other tissues of various types. This gene fluxes calcium in human aortic smooth muscle cells, and therefore is involved in signal transduction.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, renal and nervous disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the kidney and/or nervous system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., kidney, lung, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., kidney, lung, brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution in kidney and lung and homology with sap47 indicates that the protein product has regulatory or direct functions in molecular exchange with body fluids and nervous system signaling.
- Polynucleotides and polypeptides corresponding to this gene are useful for treatment of disorders in kidney and nervous system.
- Preferred polypeptide fragments comprise the amino acid sequence: PFICVARNPVSRNFSSPI LARKLCEGAA (SEQ ID NO:251); and/or KEDPANTVYSTVEIPKKMENPHSLLT MPDTPRL (SEQ ID NO:252). Also preferred are polynucleotide fragments encoding these polypeptide fragments. Based on homology, it is likely that this gene is also a cell surface marker, involved in hematopoiesis.
- This gene is expressed primarily in activated macrophages, monocytes and T- cells and to a lesser extent in spleen and bone marrow.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune and hematopoietic disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., blood cells, and bone marrow, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., blood cells, and bone marrow, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising
- tissue distribution and homology to Ly-9.2 surface immunoglobulin family indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of immune and hematopoietic disorders.
- Polypeptides and polynucleotides corresponding to this gene are also be used as a marker for leukemia or a modulator of the functions of the cells of macrophage/monocyte or T-cell types.
- the translation product of this gene shares sequence homology with the Drosophila glutactin gene which is thought to be important in cell-cell interaction or cell-extracellular matrix contact.
- This gene is expressed primarily in colon tissue, aorta endothelial cells and to a lesser extent in skin, breast tissue and T-cells.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of these tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the gastrointestinal tract, vascular system or T-cell development.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of these tissue(s) or cell type(s).
- tissue or cells particularly of the digestive system, cardiovascular system, and immune system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., colon, cardiovascular tissue, skin, mammary tissue, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., colon, cardiovascular tissue, skin, mammary tissue, and blood cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution and homology to glutactin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the development and maintenance of the integrity of the basal membrane in the gastrointestinal tract and cardiovascular system.
- the expression in T-cells also indicate the protein may be involved in T-cell adhesion, cell-cell interaction and development.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, breast cancer and non-neoplastic breast diseases.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of these tissue(s) or cell type(s).
- tissue or cells particularly of the breast tissue
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., mammary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., mammary tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution and homology to MURF4 gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neoplastic or non-neoplastic breast diseases because ATPase like protein may be involved in changed metabolic states of the breast.
- polypeptide fragments comprise comprise the amino acid sequence: ASAVLLDLPNSG
- This gene maps to chromosome X, and therefore can be used in linkage analysis as a marker for chromosome X. Therefore, mutations in the translated product of this gene may be involved in Alzheimer's disease in humans, as well as other sex linked diseases. This gene can be used as a diagnostic marker for these diseases.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 132 as residues: Arg-45 to Ser-53.
- the translation product of this gene shares week sequence homology with rat N-methyl-D-aspartate receptor subunit and other proline-rich proteins which are thought to be important in neurotransmission or protein-protein intereaction. This gene is expressed primarily in synovial hypoxia and to a lesser extent in ovary, senescent cells and brain.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, synovial hypoxia.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the synovia and brain
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., synovial tissue, ovary and other reproductive tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., synovial tissue, ovary and other reproductive tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- This gene is expressed primarily in prostate and to a lesser extent in placenta and ovary.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, male and female infertility, cancer, and other hyperproliferative disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of these tissue(s) or cell type(s).
- tissue or cells particularly of the reproductive system and neoplasia
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., prostate, placenta, ovary and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., prostate, placenta, ovary and other reproductive tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 134 as residues: Pro-17 to Met-23, Ala- 30 to Trp-38, Ile-49 to Trp-54, Lys-68 to Gly-74, Thr-93 to Gly-99, Met-126 to Glu- 132, Gly-173 to Ser-178, Lys-205 to Tyr-214.
- tissue distribution of this gene in the prostate, placenta and ovary indicates that this gene product is useful for treatment/diagnosis of male or female infertility, endocrine disorders, fetal deficiencies, ovarian failure, amenorrhea, ovarian cancer, benign prostate hyperplasia, prostate cancer, and other forms of cancer of the reproductive system.
- polypeptide fragments comprise the amino acid sequence: HPIEWAINAATLSQFY (SEQ ID NO:256); CWIKYCLTLMQN AQLSMQDNIG (SEQ ID NO:257); KVSYLRPLDFEEARELFLLGQHYVF (SEQ ID NO:258); MERRCKMHKRXIAMLEPLTVDLNPQ (SEQ ID NO:259); and/or SHIV KK NNLNKSALKY YQLFLD (SEQ ID NO:260). Also preferred are polynucleotides encoding these polypeptide fragments.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune, thyroid and pineal gland disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of these tissue(s) or cell type(s).
- tissue or cells particularly of the immune and endocrine systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., thyroid and pineal gland, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., thyroid and pineal gland, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 135 as residues: Ser-2 to Ser-8,
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating/detecting immune disorders such as arthritis, asthma, immune deficiency diseases (e.g., AIDS), and leukemia, as well as treating/detecting thymus disorders (e.g., Graves Disease, lymphocytic thyroiditis, hyperthyroidism, and hypothyroidism), and treating/detecting pineal gland disorders (e.g., circadian rhythm disturbances associated with shift work, jet lag, blindness, insomnia and old age).
- immune disorders such as arthritis, asthma, immune deficiency diseases (e.g., AIDS), and leukemia
- thymus disorders e.g., Graves Disease, lymphocytic thyroiditis, hyperthyroidism, and hypothyroidism
- pineal gland disorders e.g., circadian rhythm disturbances associated with shift work, jet lag, blindness, insomnia and old age.
- polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, pulmonary or immune disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of these tissue(s) or cell type(s).
- tissue e.g., pulmonary tissue, and tonsils, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 136 as residues: Glu-28 to Gly-49.
- tissue distribution of this gene only in lung indicates that it could play a role in the treatment/detection of lung lymphoma or sarcoma formation, pulmonary edema and embolism, bronchitis and cystic fibrosis.
- Its expression in tonsils indicates a potential role in the treatment/detection of immune disorders such as arthritis, asthma, immune deficiency diseases (e.g., AIDS), and leukemia, in addition to the treatment/detection of tonsillitis.
- polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic and immune disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of these tissue(s) or cell type(s).
- tissue and cell types e.g., blood cells, myeloid cells, and bone marrow, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- polypeptide fragments comprising the amino acid sequence: FTHLSTCLLSLLLVRMSGFLLLARASPSI CALDSSCFVEYCSSYSSSCFLHQHFPSLLDHLCQ (SEQ ID NO:261); or FLLL ARASPSICALDSSCFVQEY (SEQ ID NO:262). Also preferred are polynucleotide fragments encoding these polypeptide fragments.
- This Drosophila gene is thought to be a homolog of the global negative transcriptional regulator NOT2 (CDC36) from yeast, which modifies gene expression and suppresses position effect variegation.
- Preferred polypeptide fragments comprise the amino acid sequence: PDGRVTNIPQGMVTDQFGMIGLLTFIRAAETDPGMVHL ALGSDLTTLGLNLNS (SEQ ID NO:263); VHLALGSDLTTLGLNLNSPENLYP (SEQ ID NO:265); EDLLFYLYYMNGGDVLQLLAAVELFNRDWRYHKEERVWI TR (SEQ ID NO:264); and or HNEDFPALPGS (SEQ ID NO:266).
- This gene is expressed primarily in placenta and to a lesser extent in infant brain.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative and developmental disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the neurological system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., placenta, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., placenta, and brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 138 as residues: Leu-9 to Tyr-15, Asp-34 to Gln-46, Pro-51 to Asp-57, Gly-88 to Thr-104, Thr-123 to Ser-128.
- the tissue distribution of this gene indicates that it could be used in the detection and or treatment of neurological disorders such as such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, and panic disorder.
- This gene is expressed primarily in adrenal gland tumor and osteoclastoma.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, endocrine and bone disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the endocrine system and in bone
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., adrenal gland, and bone, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue or detection of this gene indicates that it may be involved in the treatment and or detection of adrenal gland tumors, osteosarcomas, endocrine disorders and bone disorders.
- FEATURES OF PROTEIN ENCODED BY GENE NO: 16 The translation product of this gene shares sequence homology with the FK506 binding protein, a protein which plays an important role in immunosupression.
- FKBP-12 a 12-kDa FK506-binding protein
- FKBP-12 is a cytosolic receptor for the immunosuppressants FK506 and rapamycin.
- Preferred polypeptides comprise the amino acid sequence: GRIIDTSLTRDPLVIELGQKQVIPGLEQSLLDMCVGEKRRAIIPSH LAYGKRGFPPSVPADAVVQYDVELIALIR (SEQ ID NO:267); and/or IHYTGSLV DGR IIDTS (SEQ ID NO:268). Also preferred are the polynucleotide fragments encoding these polypeptides. This gene is expressed primarily in melanocytes.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer and other hyperproliferative disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., melanocytes, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 140 as residues: Ala-118 to Phe- 124, Arg-178 to Lys-201.
- the translation product of this gene shares sequence homology with the rat calcium-activated potassium channel rSK3, which is thought to be important in regulating vascular tone. (See Accession No. gi!2564072, gil 1575663, and gill 575661.) Although homologous to these proteins, this gene contains an 18 amino acid insert, not previously identified in the homologs.
- Preferred polypeptide fragments comprise the amino acid sequence: CESPESPAQPSGSSLPAWYH (SEQ ID NO:269). Also preferred are the polynucleotide fragments encoding these polypeptides.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cardiovascular (hyper/hypotension, asthma, pulmonary edema, pneumonia, heart disease, restenosis, atherosclerosis, stoke, angina and thrombosis) and neurological disorders.
- diseases and conditions include, but are not limited to, cardiovascular (hyper/hypotension, asthma, pulmonary edema, pneumonia, heart disease, restenosis, atherosclerosis, stoke, angina and thrombosis) and neurological disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., blood cells, brain and other tissue of the nervous system, and endothelium, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 141 as residues: Glu-72 to Gly-82, His-90 to Val-95, Gln-168 to Lys-174, Val- 202 to Ser-212.
- the tissue distribution and homology to calcium-activated potassium channels indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of vascular disorders (hyper/hypotension, athesma, pulmonary edema, pneumonia, heart disease, restenosis, atherosclerosis, stoke, angina and thrombosis).
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cardiovascular (hypertension, heart disease, athesma, pulmonary edema, restenosis, atherosclerosis, stoke, angina, thrombosis, and wound healing), and neurological disorders.
- diseases and conditions include, but are not limited to, cardiovascular (hypertension, heart disease, athesma, pulmonary edema, restenosis, atherosclerosis, stoke, angina, thrombosis, and wound healing), and neurological disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the cardiovascular and neurological systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., smooth muscle, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., smooth muscle, and brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those compris
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cadiovascular disorders (hypertension, heart disease, athesma, pulmonary edema, restenosis, atherosclerosis, stoke, angina, thrombosis, and wound healing).
- cadiovascular disorders hypertension, heart disease, athesma, pulmonary edema, restenosis, atherosclerosis, stoke, angina, thrombosis, and wound healing.
- Expression in brain indicates a role in the treatment and diagnosis of behavioral or neurological disorders, such as depression, schizophrenia, Alzheimer's disease, mania, dementia, paranoia, and addictive behavior.
- polypeptide fragments comprise the amino acid sequence: EEAGAGRRCSHGGARPAGLGNEGLGLGGDPDHTDTGSRSKQRINN WKESKHKVIMASASARGNQDKDAHFPPPSKQSLLFCPKSKLHIHRAEISK (SEQ ID NO:270); and/or SKQRINNWKESKHKVIMASASAR (SEQ ID NO:271). Also preferred are the polynucleotide fragments encoding these polypepides.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation, immune and cardiovascular disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of these tissue(s) or cell type(s).
- tissue and cell types e.g., T-cells and other blood cells, endothelial cells, and pineal gland, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 143 as residues: Phe-71 to Arg-76, Pro- 82 to His-87, Glu- 103 to Ala-111.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immune, immuno-supressive (e.g. transplantation) and immunodeficiencies (e.g. AIDS) and hematopoietic disorders.
- expression in the pineal gland might suggest a role in the diagnosis of specific brain tumors and treatment of neurological disorders.
- Endothelial cell expression might suggest a role in cadiovascular or respiratory/pulmonary disorders or infections (athesma, pulmonary edema, pneumonia).
- This gene is expressed primarily in brain and embryo and to a lesser extent in leukocytes. This gene maps to chromosome 15, and therefore can be used as a marker in linkage analysis to chromosome 15.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental and neurological disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the central nervous and immune systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 144 as residues: Met-1 to Gly-8.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune disorders including: leukemias, lymphomas, auto-immune, immuno-supressive (e.g. transplantation) and immunodeficiencies (e.g. AIDS) and hematopoietic disorders.
- immuno-supressive e.g. transplantation
- immunodeficiencies e.g. AIDS
- hematopoietic disorders hematopoietic disorders.
- the expression in the brain and in particular the fetal brain — would suggest a possible role in the treatment and diagnosis of developmental and neurodegenerative diseases of the brain and nervous system (depression, schizophrenia, Alzheimer's disease, mania, dementia, paranoia, and addictive behavior).
- This gene is expressed primarily in brain, kidney, lung, liver, spleen, and a variety of leukocytes (especially T-cells) and to a lesser extent in a variety of other tissues and cell types.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, leukemias, lymphomas, autoimmune, immunosuppressive, and immunodeficiencies, hematopoietic disorders, as well as renal disorders, and neoplasms.
- diseases and conditions include, but are not limited to, leukemias, lymphomas, autoimmune, immunosuppressive, and immunodeficiencies, hematopoietic disorders, as well as renal disorders, and neoplasms.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the renal, pulmonary, immune, and central nervous systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., brain and other tissue of the nervous system, kidney, pulmonary tissue, liver, spleen, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., brain and other tissue of the nervous system, kidney, pulmonary tissue, liver, spleen, and blood cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodi
- the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of renal conditions, such as acture renal failure, kidney fibrosis, and kidney tubule regeneration.
- the expression in leukocytes and other immune tissues indicates a role in immune disorders including: leukemias, lymphomas, auto-immune, immuno-supressive (e.g. transplantation) and immunodeficiencies (e.g. AIDS) and hematopoietic disorders.
- the expression in the brain — and in particular the fetal brain — indicates a possible role in the treatment and diagnosis of developmental and neurodegenerative diseases of the brain and nervous system (depression, schizophrenia, Alzheimer's disease, mania, dementia, paranoia, and addictive behavior).
- This gene is expressed primarily in skin (fetal epithelium, keratinocytes and skin). This gene also maps to chromosome 19, and therefore can be used in linkage analysis as a marker for chromosome 19.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, skin cancers (e.g., melanomas), eczema, psoriasis or other disorders of the skin.
- diseases and conditions include, but are not limited to, skin cancers (e.g., melanomas), eczema, psoriasis or other disorders of the skin.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of these tissue(s) or cell type(s).
- tissue or cells particularly of the skin
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., skin and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., skin and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 146 as residues: Pro-28 to Glu-35, Ser- 39 to Phe-44, Ala-94
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of skin cancers (e.g., melanomas), eczema, psoriasis or other disorders of the skin.
- Preferred polypeptide fragments comprise the amino acid sequence: LFHWACLNERA AQLPRNTAXAGYQCPSCNGPS (SEQ ID NO:272).
- This gene is expressed primarily in epididymus, pineal gland, T-cells, as well as fetal epithelium, lung and kidney.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune, metabolic mediated disorders, and MEN.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., epididymus and other reproductive tissue, pineal gland, T-cells and other blood cells, epithelium, lung, and kidney, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental deficiencies or abnormalities as well as a host of different disorders which arise as a result of conditions in the indicated tissues or cell types.
- An area of particular interest is in the treatment and diagnosis of immune disorders including: leukemias, lymphomas, auto-immune, immuno-supressive (e.g. transplantation) and immunodeficiencies (e.g. AIDS) and hematopoietic disorders.
- the expression in the brain, and in particular the fetal brain would suggest a possible role in the treatment and diagnosis of developmental and neurodegenerative diseases of the brain and nervous system (depression, schizophrenia, Alzheimer's disease, mania, dementia, paranoia, and addictive behavior).
- Respiratory/pulmonary disorders such as athesma, pulmonary edema are also potential therapeutic areas, as well as renal conditions such as acute renal failure, kidney fibrosis and kidney tubule regeneration.
- this gene can be used in the treatment and/or detection of MEN I.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, leukemia, lymphoma, AIDS, hematopoeitic disorders.
- diseases and conditions which include, but are not limited to, leukemia, lymphoma, AIDS, hematopoeitic disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the immune and hematopoietic systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., spleen and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., spleen and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune disorders including: leukemias, lymphomas, auto-immune, immuno-supressive (e.g. transplantation) and immunodeficiencies (e.g. AIDS) and hematopoietic disorders.
- immune disorders including: leukemias, lymphomas, auto-immune, immuno-supressive (e.g. transplantation) and immunodeficiencies (e.g. AIDS) and hematopoietic disorders.
- Preferred polypeptide fragments comprise the amino acid sequence: FYIYYRPTDSDNDSDYKK DMVEGDKYWHSISHLQPETSYDIKMQCFNEGGESEFSNVMICETKARKSSGQP GRLPPPTLAPPQPPLPET RPVGTGAMVARSSDLPYLIVGVVLGSIVLIIVTFIPF CLWRAWSKQKHTTDLGFPRSALPPSCPYTMVPLGGLPGHQAVDSPTSVASVD GPVLM (SEQ ID NO.273); or YIYYRPTDSDNDSDYKKDMVEGDKYWHSISHLQ PETSYDIKMQCFNEGGESEFSNVMICETKARKS (SEQ ID NO:274).
- This gene is expressed primarily in fetal lung and kidney, human embryo and osteoclastoma stromal cells and to a lesser extent in a variety of other tissues and cell types.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental disorders and cancers, as well as pulmonary and renal disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., lung, kidney, embryonic tissue, and bone cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 149 as residues: Thr-5 to Pro- 18, Ala-76 to Thr-84.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of: osteoperosis, fracture, osteosarcoma, ossification, and osteonecrosis, as well as respiratory/pulmonary disorders, such as athesma, pulmonary edema, and renal conditions such as acute renal failure, kidney fibrosis and kidney tubule regeneration.
- polypeptide fragments comprise the amino acid sequence: NVRALLHRMPEPPKJNTAKFNNNKRKNLSL (SEQ ID NO:275).
- This gene is expressed primarily in pineal gland and skin, and to a lesser extent in lung.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological and behavior disorders; respiratory/pulmonary disorders, such as athesma, pulmonary edema; skin conditions such as eczema, psoriasis, acne and skin cancer, as well as AIDS.
- diseases and conditions include, but are not limited to, neurological and behavior disorders; respiratory/pulmonary disorders, such as athesma, pulmonary edema; skin conditions such as eczema, psoriasis, acne and skin cancer, as well as AIDS.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., blood cells, pineal gland, epidermis, and pulmonary tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO:150 as residues: Gln-15 to Gln-20.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions which affect the above tissues, such as: skin cancer, eczema, psoriasis, acne, athesma, pulmonary edema, neuro-degenerative or developmental disorders such as Alzheimer's, depression, schizophrenia, dementia, and AIDS.
- Preferred polypeptide encoded by this gene comprise the following amino acid sequence: NTNQREALQYAKNFQPFALNHQKDIQVLMGSLVYLRQGIENSPYVHL LDANQWADICDIFTRDACALLGLSVESPLSVSFSAGCVALPALINIKAVIEQRQC TGVWNQKDELPffiVDLGKKCWYHSIFACPILRQQTTDNNPPMKLVCGHIISRD ALNKMFNGSKLKCPYCPMEQSPGDAKQIFF (SEQ ID NO:276).
- Polynucleotides encoding such polypeptides are also provided as are complementary polynucleotides thereto.
- This gene is expressed primarily in liver (adult and fetal) and spleen tissue, and to a lesser extent in placenta, T helper cells, kidney tumor, ovarian tumor, melanocytes and fetal heart.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune and developmental diseases and disorders and liver diseases such as liver cancer.
- diseases and conditions which include, but are not limited to, immune and developmental diseases and disorders and liver diseases such as liver cancer.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., liver, spleen, placenta, blood cells, kidney, ovary and other reproductive tissue, melanocytes, and heart, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that the protein products of this gene are useful for study, diagnosis and treatment of growth, hematopoietic and immune system disorders particularly related to the liver.
- polypeptides encoded by this gene comprise the following amino acid sequence: SYLSACFAGCNSTNLTGCACLTTVPAENATVVPGKCPSPGCQEAFLTFLCVMCI CSLIGAMARHP (SEQ ID NO:277); and/or PSVULIRTVSPELKSYALGVLFLLLRL LGFIPPPLIFGAGIDSTCLFWSTFCGEQGACVLYDNVVYRYLYVSIAIALKSFAFI (SEQ ID NO:278).
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, metabolic, immune and endocrine diseases and disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the metabolic, immune and endocrine systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., endocrine tissue, hematopoietic tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., endocrine tissue, hematopoietic tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an
- tissue distribution and homology to prostaglandin (and anion) transporter indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis and treatment of endocrine, metabolic, immune and kidney disorders.
- This gene is expressed primarily in early stage human lung.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, growth and respiratory disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue e.g., pulmonary tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 153 as residues: Val-50 to Trp-55.
- tissue distribution indicates that the protein products of this gene are useful for study, diagnosis and treatment of respiratory and growth diseases and disorders.
- polypeptides encoded by this gene comprise the following amino acid sequence: QSLFTRFVRVGVPTVDLDAQGRARA SLCXXYNWRYKNLGNLPHVQLLPEFSTANAGLLYDFQLINVEDFQGVGESEPN PYFYQNLGEAEYVVALFMYMCLLGYPADKISILTTYNGQKHLIRDIINRRCGNN PLIGRPNKVTTVDRFQGQQNDYILLSLVRTRAVGHLRDVRRLNVAMSRAR (SEQ ID ⁇ O:279); and/or LVKEAKIIAMTCTHAALKRHDLVKLGFKYDNILMEE AAQILEffiTFIPLLLQNPQDGFSRLKRWIMIGDHHQLPPVI (SEQ ID NO:280).
- This gene is expressed primarily in testes tumor and to a lesser extent in adrenal gland tumor and placenta.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers and endocrine/growth disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the endocrine, developmental, and reproductive systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., testes and other reproductive tissue, adrenal gland, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., testes and other reproductive tissue, adrenal gland, and placenta, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution and homology to DNA helicase indicates that the protein products of this gene are useful for study, treatment, and diagnosis of many cancer types, including testicular cancer; as well as disorders involving endocrine function and normal growth and development.
- the translation product of this gene shares sequence homology with BID- apoptotic death gene (mouse), Genbank accession no. PID gl669514, which is thought to be important in programmed cell death. This gene is expressed primarily in jurkat membrane bound poly somes and activated neutrophils and to a lesser extent in endothelial cells and human cerebellum.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers and other proliferative disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., blood cells, endothelium, and brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 155 as residues: Glu-4 to Leu-11, Cys-28 to Arg-35, Gln-50 to His-66, Glu-73 to Gln-79, Gly-94 to Ser-100, Arg-114 to Asp-126, Pro-139 to Lys-146.
- Apoptosis - programmed cell death - is a physiological mechanism involved in the deletion of peripheral T lymphocytes of the immune system, and its dysregulation can lead to a number of different pathogenic processes.
- cancers such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, such as breast cancer, prostrate cancer, Kaposiis sarcoma and ovarian cancer
- autoimmune disorders such as systemic lupus erythematosus and immune-related glomerulonephritis rheumatoid arthritis
- viral infections such as herpes viruses, pox viruses and adeno viruses
- inflammation graft vs. host disease, acute graft rejection, and chronic graft rejection.
- Diseases associated with increased apoptosis include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration); myelodysplastic syndromes (such as aplastic anemia), ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.
- the invention provides a method of enhancing apoptosis in an individual by treating the individual with a polypeptide encoded by this gene.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, leukemia and other cancers, and metabolic disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., T-cells and other blood cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 156 as residues: Pro-22 to Gly-48, Ser-54 to Pro-61.
- the tissue distribution indicates that the protein products of this gene are useful for study of mechanisms leading to cancer, treatment and diagnosis of cancerous and pre-cancerous conditions; as well as the study and treatment of various metabolic diseases and disorders.
- polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and other disorders of the CNS.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the CNS and immune systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., meningima and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., meningima and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 157 as residues: Asn-23 to Pro-31.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune and inflammatory disorders and wound healing and tissue repair dysfunctions.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., monocytes and other blood cells, and epithelium, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 158 as residues: Ala-28 to Ala-33, Gly-35 to Glu-45.
- tissue distribution indicates that the protein products of this gene are useful for diagnosis, study and treatment of immune and inflammatory disorders and wound healing dysfunctions.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, skeletal and neoplastic conditions such as bone and prostate cancer.
- diseases and conditions which include, but are not limited to, skeletal and neoplastic conditions such as bone and prostate cancer.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune and skeletal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., bone, and prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., bone, and prostate, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 159 as residue
- tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of skeletal disorders and cancer.
- This gene is expressed primarily in Hodgkin's lymphoma, erythroleukemia cells, and TNF activated synovial fibroblasts, to a lesser extent in ovarian cancer, cerebellum, spleen, fetal liver and placenta and finally to a lesser extent in various other mesenchymal tissues.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer, immune, hematopoietic and cardiovascular disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., heart and other cardiovascular tissue, lymphoid tissue, blood cells, bone marrow, ovary and other reproductive tissue, brain and other tissue of the nervous system, spleen, liver, and mesenchymal tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 160 as residues: Lys-41 to Met-49, Gln-54 to Glu-59, Glu-76 to Thr-88.
- the homology of this gene and translation product to congenital heart disease protein 5 indicates a role for this protein in the diagnosis, prognosis and/or treatment of heart disease or other cardiovascular related disorders.
- immune and hematopoetic diseases such as lupus, transplant rejection, allergic reactions, arthritis, asthma, immunodeficiency diseases, leukemia, AIDS, thymus disorders such as Graves Disease, lymphocytic thyroiditis, hyperthyroidism and hypothyroidism, graft versus host reaction, graft versus host disease, transplant rejection, myelogenous leukemia, bone marrow fibrosis, and myeloproliferative disease.
- immune and autoimmune diseases such as lupus, transplant rejection, allergic reactions, arthritis, asthma, immunodeficiency diseases, leukemia, AIDS, thymus disorders such as Graves Disease, lymphocytic thyroiditis, hyperthyroidism and hypothyroidism, graft versus host reaction, graft versus host disease, transplant rejection, myelogenous leukemia, bone marrow fibrosis, and myeloproliferative disease.
- the protein could also be used to enhance or protect proliferation, differentiation and functional activation of hematopoietic progenitor cells such as bone marrow cells, which could be useful for cancer patients undergoing chemotherapy or patients undergoing bone marrow transplantation.
- the protein may also be useful to increase the proliferation of peripheral blood leukocytes, which could be useful in the combat of a range of hematopoietic disorders including immunodeficiency diseases, leukemia, and septicemia.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, urogenital neoplasias.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the reproductive system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., ovary and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., ovary and other reproductive tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 161 as residues: Asn-22 to Asn-
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis and treatment of ovarian and other tumors.
- the translation product of this gene shares sequence homology with zinc finger proteins.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune and growth disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., fetal tissue, and endothelial cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that the protein products of this gene are useful for study, diagnosis and treatment of immune and developmental conditions and cancer.
- This gene is expressed primarily in fetal, infant, and adult brain and to a lesser extent in other brain and endocrine organs and blastomas.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, brain tumors and neurodegenerative conditions.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the nervous and endocrine systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., brain and other tissue of the nervous system, endocrine tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., brain and other tissue of the nervous system, endocrine tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- the tissue distribution indicates that the protein products of this gene are useful for the study, diagnosis and treatment of brain cancer and other neurological disorders.
- polypeptides encoded by this gene comprise the following amino acid sequence: DTYPNEEKQQERVFPXXSAMVNNGSLSYDHER DGRPTELGGCXAWRNLHYDTFLV ⁇ iYVKRHLTMMDIDGKHEWRDCIEVPGV RLPRGYYFGTSS ⁇ TGDLSDNHDVISLKLFELTVERTPEEE (SEQ ID NO:281); and/or LKREHSLSKPYQGVGTGSSSLWNLMGNAMVMTQYIRLTPDMQSKQGA LWNRVPCFLRDWELQVHFKIHGQGKKNLHGDGLAIWYT (SEQ ID NO:282).
- polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological and neurodevelopmental conditions.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the nervous and hormonal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., brain and other tissue of the nervous system, endocrine tissue, and tissue and cells of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., brain and other tissue of the nervous system, endocrine tissue, and tissue and cells of the immune system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- tissue or cell sample taken from an individual having such a disorder
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 164 as residues: Pro-64 to Gly-71, Gly- 94 to Leu-100, Thr-110 to Pro-116, Thr-135 to Arg-145, Glu-164 to Glu-171, Asp- 204 to As ⁇ -211, Arg-253 to His-261, Asn-312 to Tyr-323.
- tissue distribution indicates that the protein products of this gene are useful for the study, diagnosis and treatment of mental retardation and other neurological disorders and neoplasias.
- This gene displays homology to the glycosyltransferase family, which catalyze the addition of sialic acids to carbohydrate groups which are present on glycoproteins. This gene is expressed primarily in smooth muscle and to a lesser extent in pineal gland, fetal liver, and infant brain.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, gastrointestinal injury, inflammatory and neurodegenerative conditions.
- diseases and conditions which include, but are not limited to, gastrointestinal injury, inflammatory and neurodegenerative conditions.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the immune and nervous systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., smooth muscle, pineal gland, liver, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., smooth muscle, pineal gland, liver, and brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those compris
- tissue distribution indicates that the protein products of this gene are useful for the study, diagnosis and treatment of neurodegenerative and growth disorders and gastrointestinal repair.
- the translation product of this gene shares sequence similarity with metallothionein polypeptides. See, for example, Proc. Natl. Acad. Sci. U S A 1992 Jul 15:89(14):6333-6337.
- Metallothioneins are believed to inhibit neuronal survival among other biological functions.
- sequence similarity especially the conserved cysteine motifs characteristic of the metallothionein family
- the translation product of this gene is expected to share certain biological activities with other members of the metallothionein polypeptide family.
- Preferred polypeptides encoded by this gene comprise the following amino acid sequence: PGTLQCSALHHDPGCANCSRFCRD CSPPACQC (SEQ ID NO:283).
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic and immune disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., placenta, liver, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution and homology to metallothionien indicates that the protein products of this gene are useful for diagnosis and treatment of immune and hematopoietic system disorders and neurological diseases, especially in fetal development.
- polypeptides encoded by this gene comprise the following amino acid sequence: FLYDVLMXHEAVMRTHQIQLPDPEFPS (SEQ ID NO:284). This gene is expressed primarily in T-cells and synovial tissue. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., synovial tissue, and T-cells and other blood cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that the protein products of this gene are useful for treatment and diagnosis of disorders of the immune system.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders of the reproductive system, the endocrine system, the hematopoietic system and the CNS.
- diseases and conditions include, but are not limited to, disorders of the reproductive system, the endocrine system, the hematopoietic system and the CNS.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the immune, endocrine, CNS and reproductive system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., ovary and other reproductive tissue, thymus, adrenal gland, brain and other tissue of the nervous system, hematopoietic tissue, and adipose tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID
- the tissue distribution and homology to methyltransferase indicates that the protein products of this gene are useful for diagnosis and treatment of disorders of the CNS, the hematopoietic system and reproductive organs and tissues.
- the abundant expression in the ovary may indicate that the gene product can be used as a hormone with either systemic or reproductive functions; as growth factors for germ cell maintenance and in vitro culture; as a fertility control agent; remedy for sexual dysfunction or sex development disorders; diagnostics/treatment for ovarian tumors, such as serous adenocarcinoma, dysgerminoma, embryonal carcinoma, choriocarcinoma, teratoma, etc;
- the expression in thymus may indicate its utilities in T- cell development and thus its applications in immune related medical conditions, such as infection, allergy, immune deficiency, tissue/organ transplantation, etc.
- This gene is expressed primarily in adipose tissue, kidney and fetal brain and to a lesser extent in several other tissues and organs.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, metabolic diseases involving especially adipose tissue, brain and kidney.
- diseases and conditions which include, but are not limited to, metabolic diseases involving especially adipose tissue, brain and kidney.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the CNS and vascular system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., adipose tissue, kidney, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., adipose tissue, kidney, brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include
- tissue distribution and homology to cytochrome C oxidase, estrogen response gene product and siliocis related gene product indicates that the protein products of this gene are useful for diagnosis and treatment of metabolic disorders in the CNS, adipose tissue and kidney, particularly siliocis.
- This gene is expressed primarily in breast, endothelial cells, synovial, heart and smooth muscle cells.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the breast, vascular and skeletal/cardiac muscular system.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., mammary tissue, endothelial cells, synovial tissue, heart and other cardiovascular tissue, and smooth muscle, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 170 as residues: Gly-16 to Arg-32, Ala-42 to Asn-50, Glu-66 to Gln-76, Arg-85 to Gly-94, Thr-108 to Asp-115, Trp-121 to Gly-130. Leu- 137 to His- 144, Glu- 155 to Lys- 161, Asp- 175 to Ser- 180, Glu-209 to Gly-217, Glu- 232 to Glu-237, Thr-243 to Asp-261, Glu-287 to Arg-295.
- the tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of diseases of the vascular and skeletal/cardiac muscular system.
- the homology of the gene with reticulocalbin indicates its biological function in regulating calcium store, a particularly important function in muscular cell types.
- the gene expression in the heart may indicate its utilities in diagnosis and remedy in heart failure, ischemic heart diseases, cardiomyopathy, hypertension, arrhythmia, etc.
- the abundant expression in the breast may indicate its applications in breast neoplasia and breast cancers, such as fibroadenoma, papillary carcinoma, ductal carcinoma, Pagetis disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma; juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases, etc.
- the translation product of this gene shares weak sequence homology with H+- transporting ATP synthase which is thought to be important in cell metabolism or signal transduction. This gene is expressed only in testis.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of some types of diseases and conditions.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the brain and hematopoietic tissues
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., testes and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., testes and other reproductive tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- testes Since only one out of about a million expressed sequence tag is found in testes indicates that its expression is low and selectively in testes. Since some of the genes only expressed in testes are usually expressed in brain or in certain induced hematopoietic cells/tissues, it is speculated that this gene to be expressed in brain or hematopoietic cells/tissues and is useful for diagnosis and treatment of disorders these systems.
- polypeptides of the invention comprise the sequence GWYWCG (SEQ ID NO:285). Polynucleotides encoding these polypeptides are also encompassed by the invention.
- This gene is expressed primarily in placenta and to a lesser extent in corpus callosum and fetal liver and spleen.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders of the immune system, e.g. autoimmune diseases and immunodeficiency.
- diseases and conditions which include, but are not limited to, disorders of the immune system, e.g. autoimmune diseases and immunodeficiency.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the immune system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., placenta, liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., placenta, liver, and spleen, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 172 as residues: Tyr-37 to Cys-49, Gly-51 to Tyr-56, Lys-88 to Trp-93, Leu-130 to Glu-136.
- tissue distribution and homology to human polymeric immunoglobulin receptor indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders, e.g. autoimmune diseases and immunodeficiencies.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorder.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the immune system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., thymus and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., thymus and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders, e.g. autoimmunity and immunodeficiency.
- Preferred polypeptide encoded by this gene comprise the following amino acid sequence: MKVGARIRVKMSVNKAHPVVSTHWRWPAEWPQMFLHLAQEPRTE VKSRPLGLAGHRQDSKTRKPLEQETIMSAADTALWPYGHGNREHQENELQKY LQYKDMHLLDSGQSLGHTHTLQGSHNLTALNI (SEQ ID NO:286).
- Polynucleotides encoding this polypeptide are also provided as are complementary polynucleotides thereto.
- This gene is expressed primarily in adrenal gland, pituitary, T helper cells, and breast cells and to a lesser extent in a wide variety of tissues.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the some diseases and conditions.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., adrenal gland, pituitary, T-cells and other blood cells, and mammary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., adrenal gland, pituitary, T-cells and other blood cells, and mammary tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of a wide range of disorders, such as immune and endocrine disorders.
- polypeptides of the invention comprise the sequence SLHKNSVSQISVLSGGKAKCS QFCTTGMDGGMSIWDVKSLESALKDLKI (SEQ ID NO:287). Polynucleotides encoding this polypeptide are also encompassed by the invention. This gene maps to chromosome 7. Therefore, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 7.
- This gene is expressed primarily in immune and hematopoietic tissues/cells and to a lesser extent in other tissues.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunological and hematopoietic disorders and inflammation.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., immune and hematopoietic tissue/cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 175 as residues: Lys-49 to Gln-54, Ala-61 to Arg-66, Lys-82 to Lys-87, Glu-126 to Val-133, His-136 to Ile-141, Glu-175 to Ser-187, Asp- 286 to Leu-296, Ala-298 to Ser-310.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immunological, hematopoietic, and inflammatory disorders, e.g, immunodeficiency, autoimmunity, inflammation.
- the translation product of this gene shares sequence homology with Caenorhabditis elegans R53.5 gene encoding a putative secreted protein without known function. This gene is expressed primarily in endothelial cells, brain and several highly vascularized, and tumor tissues and to a lesser extent in other tissues.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, aberrant angiogensis and tumorigenesis.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., endothelial cells, brain and other tissue of the nervous system, and vascular tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 176 as residues: Thr-43 to Asn-60, Thr- 106 to Phe- 115, Asp-122 to Arg-133, Arg-186 to Asp-192, Leu-211 to Lys-216.
- tissue distribution and homology to a C. elegans secreted protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of disorders in vascular or brain system, e.g. aberrant angiogenesis, ischemia, neurodegeneration, etc.
- polypeptides of the invention comprise the sequence EASKSSHAGLDLFSVAACHRF (SEQ ID NO:288). Polynucleotides encoding this polypeptide are also encompassed by the invention.
- polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, lymphocytic disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., T-cells and other blood cells, brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 177 as residues: Pro-3 to Thr-8, Arg-37 to Asp-46.
- the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis, treatment, and cure of lymphocytic disorders.
- polypeptides of the invention comprise the sequence: RCKKCTEGPI DLVFVIDGSKSLGEENFEVVKQF (SEQ ID NO:297); VTGHDSLTISPKAARVGL LQYSTQVH (SEQ ID NO:290); TEFTLRNFNSAKDMKKAVAHMKYM (SEQ ID NO:291); GKGSMTGLALKHMFERSFTQGEGARPF (SEQ ID NO:292); STRVP PVAAIVFTDGRAQDDVSEWASKAKANG ⁇ MYAVGVGKAIE (SEQ ID NO:293); EELQEIASEPTNKHLFYAEDFSTMDEISEKLKKGICEALEDS (SEQ ID NO:294); TQRLEEMTQRM (SEQ ID NO:295); PQGCPEQPLH (SEQ ID NO:297); VTGHDSLTISPKAARVGL LQYSTQVH (SEQ ID NO:290); TEFTLRNFNSAKDMKKAVAHMKYM (SEQ ID NO
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, abnormal placenta and pregnancy, disorder and injury in brain, prostate, and vasculature.
- diseases and conditions which include, but are not limited to, abnormal placenta and pregnancy, disorder and injury in brain, prostate, and vasculature.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the reproduction, neuronal, and vascular systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., placenta, brain and other tissue of the nervous system, prostate, lung and endometrium, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., placenta, brain and other tissue of the nervous system, prostate, lung and endometrium, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having
- tissue distribution and homology to cartilage matrix protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis, treatment, and cure of abnormalities in placenta and pregnancy, disorder and injury in brain, prostate, and vasculature.
- polypeptides of the invention compriseMAALLLRHVGRHCLRAHFSPQLCIRNAVPLGTTAKEEMERFWNKNIG SNRPLSPHJ IYS (SEQ ID NO:298); VFPLMYHTWNGIRHLMWDLGKGLKIPQL YQSG (SEQ ID NO:299); MAALLLRHVGRHCLRAH (SEQ ID NO:300); VKSLCL GPALIHTAKFAL (SEQ ID NO:301); VFPLMYHTWNGIRHLMWDLGKGL (SEQ ID NO:302).
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, metabolism disorder.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the [insert system where a related disease state is likely, e.g., immune] expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- polypeptides of the invention comprise the amino acid sequence: RVWDVRPFAPKERCVKIFQGNV (SEQ ID NO:303); HNFEKNLL RCSWSPDGSKIAAGSADRFVYV (SEQ ID NO:304); and/or WDTTSRRILYKLPG HAGSINEVAFHPDEPI (SEQ ID NO:305). Polynucleotides encoding these polypeptides are also encompassed by the invention.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation, immune and cardiovascular disorders and urogenital neoplasias.
- diseases and conditions which include, but are not limited to, inflammation, immune and cardiovascular disorders and urogenital neoplasias.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of these tissue(s) or cell type(s).
- tissue and cell types e.g., blood cells, cells, endothelial cells, ovary and other reproductive tissue, meningima, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 143 as residues: Phe-71 to Arg-76, Pro- 82 to His-87, Glu- 103 to Ala-111.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immune, immuno-supressive (e.g. transplantation) and immunodeficiencies (e.g. AIDS) and hematopoietic disorders.
- expression in ovarian tumor cells suggests that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis, and treatment of ovarian tumors, and other tumors and neoplasias.
- endothelial cell expression suggests a role in cadiovascular or respiratory/pulmonary disorders or infections (athsma, pulmonary edema, pneumonia).
- polypeptides of the invention comprise the sequence: GRIPAPAPSVPAGPDSR (SEQ ID NO:309); VRGRTVLRPGLDAEPE LSPE (SEQ ID NO:306); EQRVLERKLKKERKKEERQ (SEQ ID NO:307); ARRSG AELAWDYLCRWAQKHKNWRFQKTRQTWLLLHMYDSDKVPDEHFSTLLAYLE GLQGR (SEQ ID NO:255); and/or RLREAGLVAQHPP (SEQ ID NO:308).
- Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in epididymus, prostate cell line (LNCAP), and pituitary gland; and to a lesser extent in many other tissues.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, abnormalities of the epididymus, prostate (especially prostate cancer), and pituitary gland.
- diseases and conditions which include, but are not limited to, abnormalities of the epididymus, prostate (especially prostate cancer), and pituitary gland.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the male reproductive system and neuroendocrine system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., epididymus and other reproductive tissue, prostate, and pituitary gland, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., epididymus and other reproductive tissue, prostate, and pituitary gland, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution and homology to type I collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of abnormalities of the epididymus, prostate (especially prostate cancer), and pituitary gland.
- This gene is expressed primarily in the frontal cortex of the brain from a schizophrenic individual.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, schizophrenia.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the nervous system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of schizophrenia.
- polypeptide encoded by Gene 59 is homologous to human surface 4 integral membrane protein.
- the polypeptides of the invention comprise the sequence: TGCVLVLSRNFVQYACFGLFG ⁇ ALQTIAYSJXWDLKF LMRN (SEQ ID NO:310); SRSEGKSMFAGVPTMRESSPKQYMQLGGRVLLV LMFMTLLHFDASFFSIVQNIVG (SEQ JT»NO:311); GTAEDFADQFLRVTKQYLP HVARLCLISTFLEDGIRMFQWSEQRDYIDTTWNCGYLLAS (SEQ ID NO:312); LMRNESRS (SEQ ID NO:314); ASFLLSRTSWGTA (SEQ ID NO:315); and/or ASFLLSRTSWGTALMIL (SEQ ID NO.313). Polynucleotides encoding these polypeptides are also encompassed by the invention.
- This gene is expressed primarily in Hodgkin's lymphoma and lung; and to a lesser extent in many other human tissues.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, Hodgkin's lymphoma, tumors or other abnormalities of the lung.
- diseases and conditions which include, but are not limited to, Hodgkin's lymphoma, tumors or other abnormalities of the lung.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune and respiratory systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., lymphoid tissue, and pulmonary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., lymphoid tissue, and pulmonary tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of Hodgkin's lymphoma, tumors or other abnormalities of the lung.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, bone cancer and stomach cancer.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of bone cancer and stomach cancer and possibly other cancers.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, abnormalities of the epididymus, and breast cancer.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the epididymus and breast
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., epididymus and other reproductive tissue, lymphoid tissue, and mammary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., epididymus and other reproductive tissue, lymphoid tissue, and mammary tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of abnormalities of the epididymus, and breast cancer.
- polypeptides of the invention comprise the amino acid sequence: SMSALTRLASFARVGGRLFRSGCARTAGDGGVRHAGGGVHLEPRY RQFPQLTRSQVFQSEFFSGLMWFWILWRFWHDSEEVLGHFPYPDPSQWTDEEL GIPPDDED (SEQ ID NO:323), or fragments thereof. Polynucleotides encoding this polypeptide are also encompassed by the invention.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases affecting cellular metabolism.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., larynx, lymphoid tissue, brain and other tissue of the nervous system, heart and cardiovascular tissue, and retina, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO:208 as residues: Pro-27 to Gln-32, Arg- 42 to Glu-51.
- tissue distribution and homology to NADH dehydrogenase indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases involving cellular metabolism.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, abnormalities of the amygdala.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the amygdala
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., amygdala, and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., amygdala, and lymphoid tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 187 as residues: Gin- 17 to Glu-29, Pro-41 to Phe-46, Ser-59 to Ile-70, Thr-97 to Leu- 105.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of abnormalities of amygdala.
- This gene is expressed primarily in female bladder, and to a lesser extent in chronic synovitis and hemangiopericytoma.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, bladder cancer.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the urinary tract, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., bladder, synovial tissue, and vascular tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., bladder, synovial tissue, and vascular tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatments of defects of the urinary tract, especially bladder cancer.
- This gene is expressed primarily in fetal spleen, and to a lesser extent in hemangiopericytoma, thymus, and synovial sarcoma.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, defects of immune of hematopoietic systems.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the immune of hematopoietic systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., spleen, vascular tissue, thymus, blood cells, and synovial tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., spleen, vascular tissue, thymus, blood cells, and synovial tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having
- the protein product of this gene is useful for treatment of defects of the immune or hematopoietic systems, because of the gene's expression in thymus and spleen.
- This gene is expressed primarily in human pituitary and to a lesser extent in placenta and fetal lung.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, endocrine growth disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the endocrine system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., pituitary and other endocrine tissue, placenta, and pulmonary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., pituitary and other endocrine tissue, placenta, and pulmonary tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of growth disorders related to pituitary dysfunction.
- polypeptides of the invention comprise the sequence: DPRRPNKVLRYKPPPSE CNPALDDPTP (SEQ ID NO:317); DYMNLLGMIFSMCGLMLKLKWCAWVA VYCS (SEQ ID NO:318); FISFANSRSSEDTKQMMSSF (SEQ ID NO:316); and/or MLSISAVVMSYLQNPQPMTPPW (SEQ ID NO.319).
- Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in primary breast cancer and lymph node breast cancer and to a lesser extent in adult brain, lung cancer, colon cancer, epithelioid sarcoma, and Caco-2 cell line.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the cancer and tumor tissues
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., mammary tissue, lymphoid tissue, brain and other tissue of the nervous system, lung, colon, and epithelium, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., mammary tissue, lymphoid tissue, brain and other tissue of the nervous system, lung, colon, and epithelium, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or
- tissue distribution in a variety of cancer tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of a variety of cancer and tumor types.
- the translation product of this gene shares sequence homology with steroid membrane binding protein.
- the translation product of this gene has recently been published as progesterone binding protein. See Genbank AJ002030.
- Preferred polypeptides encoded by this gene comprise the following amino acid sequence:
- AAGDGDVKLGTLGSGSESSNDGGSESPGDAGAAAXGGGWAAAALALLTG GGE (SEQ ID NO:320).
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, breast cancer or developmental disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of breast or fetal tissues
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., mammary tissue, placenta, and fetal tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., mammary tissue, placenta, and fetal tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 192 as residues: Pro-43 to Asp-49, Gln- 54 to Pro-64, Asp-110 to Asp-118, Lys-138 to Tyr-143, Pro-150 to Asp-170.
- the tissue distribution and homology to steroid membrane binding protein and to progesterone binding protein indicates that the protein products of this gene are useful for treatment of breast cancers, especially those caused by estrogen and progesterone binding.
- Preferred polypeptides encoded by this gene comprise the following amino acid sequence: AADNYGIPRACRNSARSYGAAWLLLXPAGSSRVEPTQDISISDQLGG
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and infection .
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue distribution indicates that the protein products of this gene are useful for treatment of infection or inflammation or other events or defects involving the immune system.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological or neuro-endocrine diseases.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., brain and other tissue of the nervous system, thyroid, and stromal cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 194 as residues: Pro-65 to Cys-71.
- tissue distribution indicates that the protein products of this gene are useful for treatment and diagnosis of neurological diseases or metabolic conditions involving the neuro-endocrine system.
- This gene is expressed in T-cell helper and to a lesser extent in adult brain and adult testes.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders, meningitis or reproductive problems.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., T-cells and other blood cells, brain and other tissue of the nervous system, testes and other reproductive tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 195 as residues: Val-18 to Tyr-24, Ala-89 to Asp-99, Asp-104 to Ala-117, Leu- 121 to Pro- 136.
- the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis immune and reproductive disorders.
- the translated polypeptide of this contig has a high degree of identity with the Ob Receptor-Associated Protein deposited as GenBank Accession No. 2266638. No function has been determined for the Ob Receptor- Associated Protein, however it is expressed upon stimulation of the Ob Receptor by Leptin.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, acute lymphoblastic leukemia, hematapoetic disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., T-cells and other blood cells, endothelial cells, and bone marrow, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 196 as residues: Ser-61 to Trp-70.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of leukemia and other disorders of the primary immune system.
- this gene appears to be related to the Ob Receptor-Related Protein, it is likely that this polypeptide is also involved in the Ob/Leptin signal transduction cascade. As a result, this protein may be of use in the molecular diagnosis and therapeutic intervention of obesity and related disorders.
- the translation product of this contig has homology with furin, a protein thought to be a key endopeptidase in the constitutive secretory pathway.
- furin a protein thought to be a key endopeptidase in the constitutive secretory pathway.
- the identification and initial characterization of Furin was reported by Takahasi and colleagues (Biochem Biophys Res Commun 1993 Sep 15;195(2):1019-1026). This gene is expressed in neutrophils.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the immune system such as allergies, wound healing and antigen recognition.
- diseases of the immune system such as allergies, wound healing and antigen recognition.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., neutrophils and other blood cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of allergies or other immune disorders since neutrophils are an important part of an allergic response. Further, since this protein appears to be related to Furin, it can be used diagnostically and therapeutically to treat secretory protein processing disorders.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, of the motor activity and sensory functions that involve the central nervous system .
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the central nervous system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of neural disorders that affect cognitive functions.
- the translation product of this gene shares sequence homology with inorganic pyrophophatase which is thought to be important in the catalysis the hydrolysis of diphosphate bonds, chiefly in nucleoside di- and triphosphates and essential enzymes that are important for controlling the cellular levels of inorganic pyrophosphate (PPi).
- the bovine homolog of this gene has been identified by Yang and Wensel (J. Biol. Chem. 267:24641-24647 (1992)).
- This gene is expressed in osteoclastoma cells and to a lesser extent in epithelial cells.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, osteoporosis and other bone weakening diseases.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., bone, and epithelial cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 199 as residues: Lys-22 to Tyr-28, Asp- 64 to Lys-77, Pro-86 to Ile-91, Gln-99 to Pro-119, Tyr-169 to Asp-174, Lys-176 to Gly- 181, Trp- 189 to Asn-202, Lys-233 to Gly-239, Ser-250 to Asp-257.
- tissue distribution and homology to inorganic pyrophophatase indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of osteoporosis through the removal of bone by demineralization.
- ATP sulfurylase/APS kinase (GenBank Accession No. 2673862) which is thought to be important in biosynthesis of the activated sulfate donor, adenosine 3 '-phosphate 5'- phosphosulfate, involves the sequential action of two enzyme activities: ATP sulfurylase, which catalyzes the formation of adenosine 5 '-phosphosulfate (APS) from ATP and free sulfate, and APS kinase, which subsequently phosphorylates APS to produce adenosine 3'-phosphate 5'-phosphosulfate.
- APS adenosine 5 '-phosphosulfate
- This gene is expressed in osteoclastoma cells and to a lesser extent in developmental tissues.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, antibiotic resistant bacterial infections, osteoarthritis and other auto immune diseases.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissues or cells particularly of the immune or skeletal structure expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., bone, and developmental tissues, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., bone, and developmental tissues, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO:200 as residues: Asn- 15 to Trp-20, Ser-36 to Gly-41 , Pro-103 to Val-110, Pro-134 to Arg-143, Leu-173 to Arg-178, Ser-190 to Ala- 197, His-314 to Arg-319, Arg-354 to Asn-362, Asp-391 to Arg-397, Glu-402 to Asp-409, Asp-434 to Leu-439, Glu-441 to Arg-446, Gly-455 to Asp-462, Pro-528 to His-541, Asn-566 to Arg-571, Tyr-574 to Glu-581, Thr-589 to Glu-603.
- the tissue distribution and homology to ATP sulfurylase/APS kinase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment or detection of autoimmune diseases.
- Preferred polypeptides encoded by this gene comprise the following amino acid sequence: RITDNPEGKWLGRTARGSYGYIK TTAVEIXYDSLKLKKDSLGAPSRPIEDDQEVYDDVAEQDDISSHSQSGSGGIFPP PPDDDIYDGffiEEDADDGFPAPPKQLDMGDEVYDDVDTSDFPVSSAEMSQGTNV GKAKTEEKDLKKLKKQXKEXKDFRKKFKYDGEIRVLYSTKVTTSITSKKWGT RDLQVKPGESLEVIQTTDDTKVLCRNEEGKYGYVLRSYLADNDGEIYDDIADGC IYDND (SEQ ID NO:322). This gene is expressed in CD34 positive cells (hematopoietic progenitor cells) and to a lesser extent in adult spleen derived from a chronic lymphocytic leukemia patient.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, chronic lymphocytic leukemia; hematopoietic disorders.
- diseases and conditions which include, but are not limited to, chronic lymphocytic leukemia; hematopoietic disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., T-cells and other blood cells, bone marrow, hematopoietic cells, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., T-cells and other blood cells, bone marrow, hematopoietic cells, and spleen, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene
- nucleic acids and polypeptides of the present invention are useful both diagnostically and therapeutically in the intervention of immune and other disorders in which the ability to alter IL-2 expression is desired.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO.201 as residues: Ala- 17 to Lys-37, Val-39 to Ser-45, Lys-59 to His-70, Arg-90 to Leu-95, Lys-97 to Lys-107, Ser- 117 to Leu-124, Phe-133 to Ser-138, Trp- 146 to Leu-167, Pro-175 to Asn-185, Lys-190 to Ser-211, Pro-213 to Ser-222, His- 230 to Pro-235, Pro-240 to Pro-246, Pro-253 to Gly-261, Leu-271 to Leu-303, Leu- 305 to Leu-326, Lys-343 to Leu-349, Thr-363 to Leu-371, Arg-373 to Tyr-381, Tyr- 391 to Leu
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of a variety of hematopoietic disorders.
- the noted expression of this gene in the hematopoietic progenitor cell compartment - as determined by its expression on CD34 positive hematopoietic stem and progenitor cells - indicates that it plays a critical role in the expansion or proliferation of hematopoietic stem/progenitor cells, as well as in the differentiation of the various blood cell lineages. Thus it could be useful in the reconstitution of the hematopoietic system of patients with leukemias and other hematopoietic diseases.
- HAII heparin cofactor II
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, thrombopienia T-cell lymphomas; Hodgkin's lymphoma.
- diseases and conditions which include, but are not limited to, thrombopienia T-cell lymphomas; Hodgkin's lymphoma.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., T-cells and other blood cells, and lymphoid tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- HCII heparin cofactor II
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic disorders particularly in thrombopoesis, most notably of the T-cell compartment. This could include immune modulation, inflammation, immune surveillance, graft rejection, and autoimmunity.
- the translation product of this gene shares sequence homology with a mouse protein believed to represent an integral membrane protein.
- This gene is expressed in fetal cochlea and epididymus and to a lesser extent in adult spleen and osteoclastoma.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, osteoclastoma; disorders of the inner ear; male fertility disorders.
- diseases and conditions which include, but are not limited to, osteoclastoma; disorders of the inner ear; male fertility disorders.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the inner ear; male reproductive tract; bone; and immune systems
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cochlea, epididymus and other reproductive tissue, spleen, and bone, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissues e.g., cochlea, epididymus and other reproductive tissue, spleen, and bone, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO:203 as residues: Lys-13 to Gly-23, Cys-38 to Asp-43, Gly-48 to Trp-53, Cys-223 to Ile-237, Ile-240 to Ser-246.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of hearing and fertility disorders. Likewise, it may have a role in the modulation of immune function and in the treatment of osteoporosis.
- the translation product of this gene shares sequence homology with reticulocalbin which is thought to be important in the binding of calcium, particularly within the endoplasmic reticulum.
- This gene is expressed in endothelial cells and stromal cells and to a lesser extent in osteoblasts, osteoclasts, and T-cells.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, osteoperosis; osteoclastomas; T-cell lymphomas; Hodgkin's disease.
- diseases and conditions which include, but are not limited to, osteoperosis; osteoclastomas; T-cell lymphomas; Hodgkin's disease.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., endothelial cells, stromal cells, bone, T-cells and other blood cells, and lymphoid tissue, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO:204 as residues: Lys-20 to Arg-27, Pro-32 to Asp-48, Leu-64 to Arg-72, Asp-108 to Lys-114, Glu- 128 to Thr-133, Asp-139 to Phe-147, Thr-196 to Ala-204, Tyr-218 to Glu-228, Val-230 to Gln-236, Arg-241 to Lys-255, Glu-276 to Lys-287.
- tissue distribution and homology to reticulocalbin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of bone disorders such as osteoporosis; the diagnosis and treatment of T-cell lymphomas and Hodgkin's lymphoma; and the treatment of diseases and defects of the vasculature, such as vascular leak syndrome and aberrant angiogenesis that accompanies tumor growth.
- the translation product of this gene shares sequence homology with a family of peptide transport genes - particularly the A.PTR2-B gene from Arabidopsis - which are thought to be important in the uptake of small peptides.
- This gene is expressed in a number of fetal tissues, most notably lung, brain, cochlea, and liver/spleen, and to a lesser extent in osteoclastoma and endometrial tumors.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, osteoclastoma; endometrial tumors; cancer; leukemias.
- diseases and conditions which include, but are not limited to, osteoclastoma; endometrial tumors; cancer; leukemias.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue e.g., fetal tissue, pulmonary tissue, bone, brain and other tissue of the nervous system, cochlea, liver, and spleen, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO:205 as residues: Lys- 186 to Asn- 199, Pro-202 to Ala-207.
- tissue distribution and homology to peptide transport genes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the control of cell proliferation, owing to its strong expression in fetal tissues undergoing active cell division, as well as its expression in a variety of tumors or cancers of adult tissues. Potentially, it may regulate the uptake of peptides that stimulate cell proliferation. This gene product may also be useful in stimulating the uptake of a variety of peptide-based drug compounds.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer and tumors of a hematopoietic and/or endothelial cell origin; leukemias.
- diseases and conditions which include, but are not limited to, cancer and tumors of a hematopoietic and/or endothelial cell origin; leukemias.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., liver, spleen, endothelial cells, vascular tissue, and tissue and cells of the immune system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO:206 as residues: Met-1 to Asp-9, Arg-66 to Gly-76, Asp- 164 to Arg- 171.
- the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of disorders of the immune system.
- Expression of this gene product in both fetal liver/spleen and endothelial cells indicates that it may be expressed in the hemangioblast, the progenitor cell for both the immune system and the vasculature. Thus, it is most likely expressed in hematopoietic stem cells, and may be useful for the expansion of hematopoietic stem and progenitor cells in conjunction with cancer treatment for a variety of leukemias.
- the translation product of this gene shares sequence homology with NADH dehydrogenase which is thought to be important in cellular metabolism.
- This gene is expressed in fetal dura mater and to a lesser extent in T-cells and hypothalamus.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases affecting cellular metabolism.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., fetal tissue, T-cells and other blood cells, and brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO:208 as residues: Pro-27 to Gln-32, Arg-42 to Glu-51.
- tissue distribution and homology to NADH dehydrogenase indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases involving cellular metabolism.
- TNF receptor associated factor a novel TNF receptor associated factor (TRAF)-interacting protein that regulates TNF receptor-mediated signal transduction. This protein is thought to be important in regulating the cellular response to tumor necrosis factor (TNF), which is an important mediator of inflammation.
- TNF tumor necrosis factor
- This gene is expressed in endothelial cells and to a lesser extent in glioblastoma and osteoblastoma.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation; glioblastoma and osteoblastoma.
- diseases and conditions which include, but are not limited to, inflammation; glioblastoma and osteoblastoma.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., endothelial cells, bone, and glial cells and tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO:209 as residues: Glu- 15 to Thr-22, Glu-46 to Leu-62, Arg-103 to Glu-119, Gln- 127 to Glu-132, Asn-152 to Trp-158, Gln-191 to Gln-210, Glu-264 to Thr-271, Tyr- 282 to Leu-288, Trp-319 to Thr-331, Glu-335 to Ser-348, Ser-353 to Ser-358, Asp- 382 to Asn-392.
- tissue distribution and homology to I-TRAF indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of inflammatory diseases, including rheumatoid arthritis, sepsis, inflammatory bowel disease, and psoriasis, particularly where tumor necrosis factor is known to be involved.
- inflammatory diseases including rheumatoid arthritis, sepsis, inflammatory bowel disease, and psoriasis, particularly where tumor necrosis factor is known to be involved.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and autoimmune diseases; T-cell lymphoma.
- diseases and conditions which include, but are not limited to, inflammation and autoimmune diseases; T-cell lymphoma.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue and cell types e.g., T-cells and other blood cells, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of inflammatory disorders such as sepsis, inflammatory bowel disease, psoriasis, and rheumatoid arthritis as well as autoimmune disease such as lupus. It could also be useful in immune modulation and in the process of immune surveillance.
- the present invention can be used diagnostically and therapeutically to treat X-linked Retinopathy.
- This gene is expressed in human brain tissue.
- polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, brain disorders; neurodegenerative disorders; tumors of a brain origin.
- diseases and conditions which include, but are not limited to, brain disorders; neurodegenerative disorders; tumors of a brain origin.
- polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
- tissue or cells particularly of the central nervous system
- expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- tissue e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues
- bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
- another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- Preferred epitopes include those comprising a sequence shown in SEQ ID NO:211 as residues: Cys-32 to
- tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of CNS disorders such as epilepsy, paranoia, depression, Alzheimer's disease, and schizophrenia. It could be useful in the survival and/or proliferation of neurons and could effect neuronal regeneration.
- Table 1 summarizes the information corresponding to each "Gene No.” described above.
- the nucleotide sequence identified as “NT SEQ ID NO:X” was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ED” identified in Table 1 and, in some cases, from additional related DNA clones.
- the overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.
- the cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date.” Some of the deposits contain multiple different clones corresponding to the same gene. "Vector” refers to the type of vector contained in the cDNA Clone ID.
- Total NT Seq refers to the total number of nucleotides in the contig identified by "Gene No.”
- the deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as “5' NT of Clone Seq.” and the "3' NT of Clone Seq.” of SEQ ID NO:X.
- the nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon.”
- the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep.”
- the translated amino acid sequence beginning with the methionine, is identified as "AA SEQ ID NO:Y,” although other reading frames can also be easily translated using known molecular biology techniques.
- the polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.
- the first and last amino acid position of SEQ ID NO: Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep.”
- the predicted first amino acid position of SEQ ID NO: Y of the secreted portion is identified as
- SEQ ID NO:X and the translated SEQ ID NO: Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below.
- SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention.
- polypeptides identified from SEQ ID NO: Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1. Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors.
- the errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence.
- the erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence.
- the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).
- the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1.
- the nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits.
- the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.
- the present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone.
- the corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.
- species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.
- polypeptides of the invention can be prepared in any suitable manner.
- Such polypeptides include isolated naturally occurring polypeptides, recombinanfly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.
- the polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification , such as multiple histidine residues, or an additional sequence for stability during recombinant production.
- the polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified.
- a recombinantly produced version of a polypeptide, including the secreted polypeptide can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988).
- Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.
- the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10: 1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.
- the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point.
- SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point.
- cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species.
- the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence.
- the naturally occurring signal sequence may be further upstream from the predicted signal sequence.
- the predicted signal sequence will be capable of directing the secreted protein to the ER.
- Variant refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention. By a polynucleotide having a nucleotide sequence at least, for example, 95%
- nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide.
- a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
- the query sequence may be an entire sequence shown inTable 1, the ORF (open reading frame), or any fragement specified as described herein.
- nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the presence invention can be determined conventionally using known computer programs.
- a preferred method for determing the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245).
- sequence alignment the query and subject sequences are both DNA sequences.
- An RNA sequence can be compared by con verting U's to T's.
- the result of said global sequence alignment is in percent identity.
- the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity.
- the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment.
- This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score.
- This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.
- a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity.
- the deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/aligmeld of the first 10 bases at 5' end.
- the 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%.
- a 90 base subject sequence is compared with a 100 base query sequence.
- deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query.
- percent identity calculated by FASTDB is not manually corrected.
- bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequnce are manually corrected for. No other manual corrections are to made for the purposes of the present invention.
- a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence.
- the amino acid sequence of the subject polypeptide may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence.
- up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid.
- These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
- any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs.
- a preferred method for determing the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245).
- the query and subject sequences are either both nucleotide sequences or both amino acid sequences.
- the result of said global sequence alignment is in percent identity.
- the FASTDB program does not account for N- and C- terminal truncations of the subject sequence when calculating global percent identity.
- the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score.
- This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence. For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N- terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus.
- the 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%.
- a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C- termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected.
- the variants may contain alterations in the coding regions, non-coding regions, or both.
- polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide are preferred.
- variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred.
- Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).
- Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.
- variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function.
- Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al, J.
- C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained.
- the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus.
- Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.
- the invention further includes polypeptide variants which show substantial biological activity.
- variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity.
- guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.
- the first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.
- the second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244: 1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.
- tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ee; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gin, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.
- variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification.
- substitutions with one or more of the non-conserved amino acid residues where the substituted amino acid residues may or may not be one encoded by the genetic code
- substitution with one or more of amino acid residues having a substituent group or fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility
- polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity.
- a "polynucleotide fragment” refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X.
- the short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length.
- a fragment "at least 20 nt in length,” for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.
- polynucleotide fragments of the invention include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401- 450, 451-500, 501-550, 551-600, 651-700, or 701 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone.
- “about” includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini.
- these fragments encode a polypeptide which has biological activity.
- polypeptide fragment refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing,” or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region.
- polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length.
- “about” includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.
- Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1- 60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.
- polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha- helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn- forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface- forming regions, substrate binding region, and high antigenic index regions.
- Polypeptide fragments of SEQ ID NO: Y falling within conserved domains are specifically contemplated by the present invention.
- polynucleotide fragments encoding these domains are also contemplated.
- Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention.
- the biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.
- epitopes refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human.
- a preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment.
- a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope.”
- an "immunogenic epitope” is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983).)
- antigenic epitopes may be produced by any conventional means.
- antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids.
- Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G.
- immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).)
- a preferred immunogenic epitope includes the secreted protein.
- the immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier.
- a carrier protein such as an albumin
- immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)
- antibody As used herein, the term "antibody” (Ab) or “monoclonal antibody” (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')2 fragments) which are capable of specifically binding to protein. Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.
- any polypeptide of the present invention can be used to generate fusion proteins.
- the polypeptide of the present invention when fused to a second protein, can be used as an antigenic tag.
- Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide.
- secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.
- domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions.
- the fusion does not necessarily need to be direct, but may occur through linker sequences.
- fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage.
- peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.
- polypeptides of the present invention can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides.
- IgG immunoglobulins
- fusion proteins facilitate purification and show an increased half-life in vivo.
- chimeric proteins consisting of the first two domains of the human CD4- polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins.
- Fusion proteins having disulfide-linked dimeric structures can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone.
- EP-A-O 464533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof.
- the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties.
- EP-A 0232 262. Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations.
- human proteins such as hIL-5
- Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5.
- the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide.
- the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available.
- hexa-histidine provides for convenient purification of the fusion protein.
- Another peptide tag useful for purification, the "HA" tag corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)
- any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.
- the present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques.
- the vector may be, for example, a phage, plasmid, viral, or retroviral vector.
- Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.
- the polynucleotides may be joined to a vector containing a selectable marker for propagation in a host.
- a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.
- the polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan.
- the expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation.
- the coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.
- the expression vectors will preferably include at least one selectable marker.
- markers include dihydrofolate reductase, G4J 8 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria.
- Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli,
- Streptomyces and Salmonella typhimurium cells
- fungal cells such as yeast cells
- insect cells such as Drosophila S2 and Spodoptera Sf9 cells
- animal cells such as CHO, COS, 293, and Bowes melanoma cells
- plant cells Appropriate culture mediums and conditions for the above-described host cells are known in the art.
- vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNHl ⁇ a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, ⁇ RIT5 available from Pharmacia Biotech, Inc.
- eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXTl and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia.
- Other suitable vectors will be readily apparent to the skilled artisan.
- Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology ( 1986).
- polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.
- a polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography (“HPLC”) is employed for purification.
- HPLC high performance liquid chromatography
- Polypeptides of the present invention can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells.
- a prokaryotic or eukaryotic host including, for example, bacterial, yeast, higher plant, insect, and mammalian cells.
- the polypeptides of the present invention may be glycosylated or may be non-glycosylated.
- polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.
- N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.
- the polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.
- sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment. Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler.
- sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments.
- Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow- sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDN A libraries.
- FISH fluorescence in situ hybridization
- the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).
- Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.
- Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease.
- Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .
- a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.
- a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 3:173 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem.
- Polynucleotides of the present invention are also useful in gene therapy.
- One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect.
- the polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner.
- Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.
- the polynucleotides are also useful for identifying individuals from minute biological samples.
- the United States military for example, is considering the use of restriction fragment length polymo ⁇ hism (RFLP) for identification of its personnel.
- RFLP restriction fragment length polymo ⁇ hism
- an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel.
- This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult.
- the polynucleotides of the present invention can be used as additional DNA markers for RFLP.
- the polynucleotides of the present invention can also be used as an alternative to
- RFLP RFLP
- DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc.
- DNA sequences amplified from polymo ⁇ hic loci such as DQa class ⁇ HLA gene, are used in forensic biology to identify individuals.
- polynucleotides of the present invention can be used as polymo ⁇ hic markers for forensic pu ⁇ oses.
- reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin.
- Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.
- the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip” or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.
- a polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques.
- protein expression in tissues can be studied with classical immunohistological methods.
- Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA).
- ELISA enzyme linked immunosorbent assay
- RIA radioimmunoassay
- Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (1251, 1211), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.
- enzyme labels such as, glucose oxidase, and radioisotopes, such as iodine (1251, 1211), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc)
- fluorescent labels such as fluorescein and rhodamine, and biotin.
- proteins can also be detected in vivo by imaging.
- Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR.
- suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject.
- suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be inco ⁇ orated into the antibody by labeling of nutrients for the relevant hybridoma.
- a protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety such as a radioisotope (for example, 1311, 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal.
- a radioisotope for example, 1311, 112In, 99mTc
- a radio-opaque substance for example, parenterally, subcutaneously, or intraperitoneally
- the quantity of radioactivity injected will normally range from about 5 to 20 miUicuries of 99mTc.
- the labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein.
- In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments.” (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc.
- the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.
- polypeptides of the present invention can be used to treat disease.
- patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).
- antibodies directed to a polypeptide of the present invention can also be used to treat disease.
- administration of an antibody directed to a polypeptide of the present invention can bind and reduce ove ⁇ roduction of the polypeptide.
- administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).
- the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art.
- Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell.
- the polypeptides of the present invention can be used to test the following biological activities.
- polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.
- a polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells.
- Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells.
- the etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious.
- a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.
- a polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells.
- a polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells.
- immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g.
- agammaglobulinemia agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HTV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.
- a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation).
- a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes.
- a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.
- a polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders.
- autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.
- autoimmune disorders examples include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus,
- Polyendocrinopathies Pu ⁇ ura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.
- allergic reactions and conditions such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention.
- these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.
- a polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD).
- Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response.
- an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues.
- the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T- cells may be an effective therapy in preventing organ rejection or GVHD.
- a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation.
- the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response.
- These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia- reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)
- SIRS systemic inflammatory response syndrome
- a polypeptide or polynucleotide can be used to treat or detect hype ⁇ roliferative disorders, including neoplasms.
- a polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions.
- a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hype ⁇ roliferative disorder.
- hype ⁇ roliferative disorders can be treated.
- This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response.
- decreasing an immune response may also be a method of treating hype ⁇ roliferative disorders, such as a chemotherapeutic agent.
- Examples of hype ⁇ roliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.
- hype ⁇ roliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention.
- hype ⁇ roliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, pu ⁇ ura, sarcoidosis, Sezary Syndrome, Waldenstron's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hype ⁇ roliferative disease, besides neoplasia, located in an organ system listed above.
- a polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated.
- the immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response.
- the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.
- viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention.
- viruses include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), He ⁇ esviridae (such as, Cytomegalovirus, He ⁇ es Simplex, He ⁇ es Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbilli virus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or
- Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox , hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia.
- a polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.
- bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellu
- a polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.
- parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas.
- These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis.
- a polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.
- treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy).
- the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.
- a polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues.
- the regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteocarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.
- Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue.
- organs e.g., pancreas, liver, intestine, kidney, skin, endothelium
- muscle smooth, skeletal or cardiac
- vascular including vascular endothelium
- nervous hematopoietic
- hematopoietic skeletal tissue
- skeletal bone, cartilage, tendon, and ligament
- a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage.
- a polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage.
- Specific diseases that could be treated include of tendinitis, ca ⁇ al tunnel syndrome, and other tendon or ligament defects.
- tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.
- nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells.
- Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stoke).
- diseases associated with peripheral nerve injuries include peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease,
- Parkinson's disease Huntington's disease, amyotrophic lateral sclerosis, and Shy- Drager syndrome
- a polynucleotide or polypeptide of the present invention may have chemotaxis activity.
- a chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hype ⁇ roliferation.
- the mobilized cells can then fight off and/or heal the particular trauma or abnormality.
- a polynucleotide or polypeptide of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hype ⁇ roliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotaxic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds. It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.
- a polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds.
- the binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound.
- Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors),or small molecules.
- the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic.
- the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.
- the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane.
- Preferred cells include cells from mammals, yeast, Drosophila, or E. coli.
- Cells expressing the polypeptide are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.
- the assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.
- the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures.
- the assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.
- an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody.
- the antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.
- the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred.
- the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity , and (b) determining if a biological activity of the polypeptide has been altered.
- a polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.
- a polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery).
- a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.
- a polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, caricadic rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.
- a polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.
- nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1. Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.
- nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.
- nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.
- an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.
- nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.
- a further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.
- a further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X. Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.
- composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.
- nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.
- nucleic acid molecule wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.
- nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.
- a further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.
- a further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.
- a further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1 ; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.
- said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group.
- said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group.
- the nucleic acid molecules can comprise DNA molecules or RNA molecules.
- a further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- the method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.
- a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1 comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- the method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.
- composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1 ; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- the nucleic acid molecules can comprise DNA molecules or RNA molecules. Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1. Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO: Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO: Y in Table 1.
- an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO: Y.
- an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y. Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.
- an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.
- said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.
- a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- the above method for identifying the species, tissue or cell type of a biological sample comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.
- a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1 comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- the step of detecting said polypeptide molecules includes using an antibody.
- an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDN A clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- an isolated nucleic acid molecule wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.
- an isolated nucleic acid molecule wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ED NO: Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.
- a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method.
- a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method. Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID
- Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.
- Example 1 Isolation of a Selected cDNA Clone From the Deposited Sample Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.
- Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated.
- the vector used to construct the library is a phage vector from which a plasmid has been excised.
- the table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap,” the corresponding deposited clone is in "pBluescript.”
- pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene.
- pBS comes in 4 forms SK+, SK-, KS+ and KS.
- S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for Sad and "K” is for Kpnl which are the first sites on each respective end of the linker).
- E. coli strain DH10B also available from Life Technologies.
- Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue.
- Vector pCR ® 2.1 which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J.
- a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.
- each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.
- Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1.
- a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.
- a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported.
- the oligonucleotide is labeled, for instance, with 32 P- ⁇ -ATP using T4 polynucleotide kinase and purified according to routine methods.
- T4 polynucleotide kinase T4 polynucleotide kinase and purified according to routine methods.
- the plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above.
- the transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.
- appropriate selection agent e.g., ampicillin
- two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template.
- the polymerase chain reaction is carried out under routine conditions, for instance, in 25 ⁇ l of reaction mixture with 0.5 ug of the above cDNA template.
- a convenient reaction mixture is 1.5-5 mM MgCl 2 , 0.01% (w/v) gelatin, 20 ⁇ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase.
- Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler.
- the amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified.
- the PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.
- RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts.
- a primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.
- RNA isolation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step.
- the phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.
- This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide.
- the first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest.
- the resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.
- a human genomic PI library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)
- Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al.
- a cDNA probe produced by the method described in Example 1 is labeled with P 32 using the rediprimeTM DNA labeling system (Amersham Life Science), according to manufacturer's instructions.
- the probe is purified using CHROMA SPIN- 100TM column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT 1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.
- MTN Multiple Tissue Northern
- H human tissues
- IM human immune system tissues
- An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated
- a polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments.
- the primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and Xbal, at the 5' end of the primers in order to clone the amplified product into the expression vector.
- restriction sites such as BamHI and Xbal
- BamHI and Xbal correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth,
- This plasmid vector encodes antibiotic resistance (Amp r ), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.
- the pQE-9 vector is digested with BamHI and Xbal and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS.
- the ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lad repressor and also confers kanamycin resistance (Kan r ). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.
- Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml).
- the O/N culture is used to inoculate a large culture at a ratio of 1 : 100 to 1 :250.
- the cells are grown to an optical density 600 (O.D. 600 ) of between 0.4 and 0.6.
- IPTG Isopropyl-B-D-thiogalacto pyranoside
- IPTG induces by inactivating the lad repressor, clearing the P/O leading to increased gene expression.
- Cells are grown for an extra 3 to 4 hours.
- Ni-NTA nickel-nitrilo-tri-acetic acid
- the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.
- the purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl.
- PBS phosphate-buffered saline
- the protein can be successfully refolded while immobilized on the Ni-NTA column.
- the recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors.
- the renaturation should be performed over a period of 1.5 hours or more.
- the proteins are eluted by the addition of 250 mM immidazole. Immidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl.
- the purified protein is stored at 4° C or frozen at -80° C.
- the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a.
- This vector contains: I) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (laclq).
- the origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD).
- the promoter sequence and operator sequences are made synthetically. DNA can be inserted into the pHEa by restricting the vector with Ndel and
- the DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for Ndel (5' primer) and Xbal, BamHI, Xhol, or Asp718 (3' primer).
- the PCR insert is gel purified and restricted with compatible enzymes.
- the insert and vector are ligated according to standard protocols.
- Example 6 Purification of a Polypeptide from an Inclusion Body
- the following alternative method can be used to purify a polypeptide expressed in E coli when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C. Upon completion of the production phase of the E. coli fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at
- the cells are then lysed by passing the solution through a microfluidizer (Microfuidics, Co ⁇ . or APV Gaulin, Inc.) twice at 4000-6000 psi.
- the homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min.
- the resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.
- the resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.
- guanidine hydrochloride (GuHCl)
- the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring.
- the refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.
- the diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins.
- the columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl.
- the CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A 280 monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.
- the resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from
- the purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.
- Example 7 Cloning and Expression of a Polypeptide in a Baculovirus Expression System
- the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide.
- This expression vector contains the strong polyhedrin promoter of the Autographa calif ornica nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718.
- the polyadenylation site of the simian virus 40 (“SV40”) is used for efficient polyadenylation.
- the plasmid contains the beta-galactosidase gene from E.
- baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIMl, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required.
- Such vectors are described, for instance, in Luckow et al., Virology 170:31- 39 (1989). Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Altematively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).
- the amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean,” BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.
- the plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art.
- the DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).
- the fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase.
- E. coli HB101 or other suitable E. coli hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates.
- Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.
- a plasmid containing the polynucleotide Five ⁇ g of a plasmid containing the polynucleotide is co-transfected with 1.0 ⁇ g of a commercially available linearized baculovirus DNA ("BaculoGoldTM baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Feigner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987).
- BaculoGoldTM virus DNA and 5 ⁇ g of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ⁇ l of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD).
- plaque assay After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, supra.
- An agarose gel with "Blue Gal” (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques.
- a detailed description of a "plaque assay” of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.
- blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf).
- the agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ⁇ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supematants of these culture dishes are harvested and then they are stored at 4° C.
- Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS.
- the cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine
- Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.
- Example 8 Expression of a Polypeptide in Mammalian Cells
- the polypeptide of the present invention can be expressed in a mammalian cell.
- a typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retro viruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).
- Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dr.fr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0.
- Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.
- the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome.
- a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.
- the transfected gene can also be amplified to express large amounts of the encoded protein.
- the DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253: 1357-1370 (1978); Hamlin, J. L. and Ma, C, Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M.
- Another useful selection marker is the enzyme glutamine synthase (GS) (Mu ⁇ hy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992).
- GS glutamine synthase
- the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.
- Derivatives of the plasmid pSV2-dhfr ATCC Accession No. 37146
- the expression vectors pC4 ATCC Accession No.
- LTR Rous Sarcoma Virus
- CMV-enhancer Boshart et al., Cell 41:521-530 (1985).
- Multiple cloning sites e.g., with the restriction enzyme cleavage sites BamHI, Xbal and Asp718, facilitate the cloning of the gene of interest.
- the vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the S V40 early promoter.
- the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art.
- the vector is then isolated from a 1% agarose gel.
- a polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)
- the amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.
- the amplified fragment is then digested with the same restriction enzyme and purified on a 1 % agarose gel.
- the isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase.
- E. coli HB 101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.
- Chinese hamster ovary cells lacking an active DHFR gene is used for transfection.
- Five ⁇ g of the expression plasmid pC6 is cotransfected with 0.5 ⁇ g of the plasmid pSVneo using lipofectin (Feigner et al., supra).
- the plasmid pSV2-neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418.
- the cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418.
- the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of metothrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6- well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM).
- methotrexate 50 nM, 100 nM, 200 nM, 400 nM, 800 nM.
- Clones growing at the highest concentrations of methotrexate are then transfened to new 6-well plates containing even higher concentrations of methotrexate (1 ⁇ M, 2 ⁇ M, 5 ⁇ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 ⁇ M. Expression of the desired gene product is analyzed, for instance, by SDS- PAGE and Western blot or by reversed phase HPLC analysis.
- polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827;
- fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo.
- Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein.
- Fusion proteins can also create chimeric molecules having more than one function.
- fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in
- the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.
- the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with
- BamHI linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced. If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)
- the antibodies of the present invention can be prepared by a variety of methods. (See, Cunent Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a prefened method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.
- the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof).
- Such monoclonal antibodies can be prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp.
- such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell.
- Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/1 of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ⁇ g/ml of streptomycin.
- the splenocytes of such mice are extracted and fused with a suitable myeloma cell line.
- a suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC.
- SP2O parent myeloma cell line
- the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).)
- the hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.
- additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies.
- a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody.
- protein specific antibodies are used to immunize an animal, preferably a mouse.
- the splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide.
- Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.
- Fab and F(ab')2 and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein.
- Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments).
- enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments).
- secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.
- “humanized” chimeric monoclonal antibodies Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Monison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No.
- the transfection should be performed by tag-teaming the following tasks.
- tags on time is cut in half, and the cells do not spend too much time on PBS.
- person A aspirates off the media from four 24- well plates of cells, and then person B rinses each well with .5-lml PBS.
- Person A then aspirates off PBS rinse, and person B, using al2-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.
- the transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period.
- Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well.
- Incubate at 37°C for 45 or 72 hours depending on the media used: 1 %BSA for 45 hours or CHO-5 for 72 hours.
- the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.
- Jaks-STATs pathway One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS” elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.
- GAS gamma activation site
- ISRE interferon-sensitive responsive element
- GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs.”
- STATs Signal Transducers and Activators of Transcription
- Statl and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread).
- Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12.
- Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.
- the STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family.
- Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jakl, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.
- the Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem.
- a cytokine receptor family capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for JL-2, IL-3, IL-4, IL-6, IL-7, EL-9, IL-11, IL- 12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10.
- the Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proxial region encoding T ⁇ -Ser-Xxx-T ⁇ -Ser (SEQ ID NO:2)).
- Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.
- activation of the Jaks-STATs pathway can be used to indicate proteins involved in the proliferation and differentiation of cells.
- growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.)
- activators of the Jaks-STATs pathway can be identified.
- IL-2 (lymphocytes) - + - + 1,3,5 GAS
- IL-7 (lymphocytes) - + - + 5 GAS
- IL-9 (lymphocytes) - + - + 5 GAS
- a PCR based strategy is employed to generate a GAS-SV40 promoter sequence.
- the 5' primer contains four tandem copies of the GAS binding site found in the IRFl promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity
- the 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an Xhol site.
- the sequence of the 5' primer is: 5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCG AAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)
- the downstream primer is complementary to the SV40 promoter and is flanked with a Hind in site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)
- PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech.
- the resulting PCR fragment is digested with Xhol/Hind III and subcloned into BLSK2-.
- a GAS:SEAP2 reporter construct is next engineered.
- the reporter molecule is a secreted alkaline phosphatase, or "SEAP.”
- SEAP secreted alkaline phosphatase
- any reporter molecule can be instead of SEAP, in this or in any of the other Examples.
- Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.
- the above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using Hindlll and Xhol, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector.
- this vector does not contain a neomycin resistance gene, and therefore, is not prefened for mammalian expression systems.
- the GAS-SEAP cassette is removed from the GAS-SEAP vector using Sail and Notl, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector.
- pGFP-1 pGFP-1
- HELA epidermal
- HUVEC endothelial
- Reh B-cell
- Saos-2 osteoblast
- HUVAC aortic
- Cardiomyocyte a cell line
- Example 13 High-Throughput Screening Assay for T-cell Activity.
- T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12.
- factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway.
- the T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TD3-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL- 1582) cells can also be used.
- Jurkat T-cells are lymphoblastic CD4+ Thl helper cells.
- approximately 2 million Jurkat cells are transfected with the GAS- SEAP/neo vector using DMRXE-C (Life Technologies)(transfection procedure described below).
- the transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml genticin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.
- the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates.
- Jurkat cells are maintained in RPMI + 10% serum with l%Pen-Strep.
- OPTI-MEM Life Technologies
- the cells On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required. Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).
- the 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transfened to an opaque 96 well plate using a 12 channel pipette.
- the opaque plates should be covered (using sellophene covers) and stored at -
- Example 14 High-Throughput Screening Assay Identifying Mveloid Activity
- the following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells.
- Myeloid cell activity is assessed using the GAS/SEAP Neo construct produced in
- Example 12 Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway.
- the myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.
- the GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418.
- the G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.
- Example 15 High-Throughput Screening Assay Identifying Neuronal Activity.
- EGRl early growth response gene 1
- PC12 cells rat phenochromocytoma cells
- TPA tetradecanoyl phorbol acetate
- NGF nerve growth factor
- EGF epidermal growth factor
- the EGR-1 promoter sequence (-633 to +l)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers: 5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6) 5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7) Using the GAS:SEAP/Neo vector produced in Example 12, EGRl amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes Xhol/Hindlll, removing the GAS/SV40 stuffer.
- PC 12 cells are routinely grown in RPMI- 1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat- inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish.
- FBS heat- inactivated fetal bovine serum
- EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418.
- the G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.
- a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI- 1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.
- PBS Phosphate buffered saline
- NF- ⁇ B Nuclear Factor KB
- NF- ⁇ B is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products.
- NF- ⁇ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF-
- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.
- I- KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes.
- Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.
- reporter constructs utilizing the NF- ⁇ B promoter element are used to screen the supernatants produced in Example 11.
- Activators or inhibitors of NF-kB would be useful in treating diseases.
- inhibitors of NF- ⁇ B could be used to treat those diseases related to the acute or chronic activation of NF-kB, such as rheumatoid arthritis.
- the upstream primer contains four tandem copies of the NF- ⁇ B binding site (GGGGACTTTCCC) (SEQ ID NO: 8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an Xhol site: 5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)
- the downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:
- PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech.
- the resulting PCR fragment is digested with Xhol and Hind UI and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:
- this vector does not contain a neomycin resistance gene, and therefore, is not prefened for mammalian expression systems.
- the NF- ⁇ B/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes Sail and Notl, and inserted into a vector containing neomycin resistance.
- the NF-KB/SV40/SEAP cassette was inserted into ⁇ GFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with Sail and Notl.
- SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure.
- the Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.
- Example 18 High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability
- Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell.
- small molecules such as calcium, potassium, sodium, and pH
- these alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell.
- this protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.
- the following assay uses Fluorometric Imaging Plate Reader ("FLIPR”) to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules.
- FLIPR Fluorometric Imaging Plate Reader
- any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.
- adherent cells seed the cells at 10,000 -20,000 cells/well in a Co-star black
- 96- well plate with clear bottom The plate is incubated in a CO 2 incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash. A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is incubated at 37°C in a CO 2 incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer. For non-adherent cells, the cells are spun down from culture media.
- Cells are re-suspended to 2-5xl0 6 cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10° cells/ml, and dispensed into a microplate, 100 ul well. The plate is centrifuged at 1000 ⁇ m for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.
- each well contains a fluorescent molecule, such as fluo-3.
- the supernatant is added to the well, and a change in fluorescence is detected.
- the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca" 1 " 4" concentration.
- the Protein Tyrosine Kinases represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the conesponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.
- cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non- receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).
- src-family e.g., src, yes, lck, lyn, fyn
- non- receptor linked and cytosolic protein tyrosine kinases such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).
- Seed target cells e.g., primary keratinocytes
- Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford,MA), or calf serum, rinsed with PBS and stored at 4°C.
- Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr.
- Falcon plate covers #3071 from Becton Dickinson (Bedford,MA) are used to cover the Loprodyne Silent Screen Plates.
- Falcon Microtest III cell culture plates can also be used in some proliferation experiments.
- A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr.
- Example 11 After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11 , the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na3VO4, 2 mM Na4P2O7 and a cocktail of protease inhibitors (# 1836170) obtained from Boeheringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for
- the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here. Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this pu ⁇ ose include PSK1 (conesponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (conesponding to amino acids 1-17 of gastrin).
- PSK1 conesponding to amino acids 6-20 of the cell division kinase cdc2-p34
- PSK2 conesponding to amino acids 1-17 of gastrin
- Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.
- the tyrosine kinase reaction is set up by adding the following components in order. First, add lOul of 5uM Biotinylated Peptide, then lOul ATP/Mg2+ (5mM ATP/50mM MgCl2), then lOul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, lmM EGTA, lOOmM MgCl2, 5 mM MnCl2 5 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(lmM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding lOul of the control enzyme or the filtered supernatant.
- the tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.
- Tyrosine kinase activity is determined by transfening 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavadin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti- phospotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-
- phosphorylation of major intracellular signal transduction intermediates
- one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases.
- phosphorylation of other molecules such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.
- assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (lug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (lOOng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.
- A431 cells are seeded at 20,000/well in a 96-well Loprodyne filte ⁇ late and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.
- DMEM basal medium
- EGF 6ng/well
- 50 ul of the supernatants obtained in Example 11 for 5-20 minutes.
- the cells are then solubilized and extracts filtered directly into the assay plate.
- Example 21 Method of Determining Alterations in a Gene Corresponding to a Polynucleotide
- RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated.
- cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.)
- the cDNA is then used as a template for PCR, employing primers sunounding regions of interest in
- SEQ ID NO:X Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991). PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.
- PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19: 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.
- Genomic rearrangements are also observed as a method of determining alterations in a gene conesponding to a polynucleotide.
- Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'- triphosphate (Boehringer Manheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991).
- Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the conesponding genomic locus.
- Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometries, Arlington, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Co ⁇ oration, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.
- Example 22 Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample
- a polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype.
- Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.
- antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample.
- Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml.
- the antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.
- the coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide.
- a sample containing the polypeptide Preferably, serial dilutions of the sample should be used to validate results.
- the plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.
- the secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners.
- the "effective amount" for pu ⁇ oses herein is thus determined by such considerations.
- the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 ⁇ g/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion.
- this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg kg/day for the hormone.
- the secreted polypeptide is typically administered at a dose rate of about 1 ⁇ g/kg/hour to about 50 ⁇ g/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump.
- An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.
- compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray.
- “Pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- parenteral refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
- sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules.
- sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res.
- Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci.
- the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.
- the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable canier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- a pharmaceutically acceptable canier i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.
- the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation.
- the canier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient.
- carrier vehicles include water, saline, Ringer's solution, and dextrose solution.
- Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.
- the carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability.
- Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpynolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.
- buffers such as phosphate,
- the secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.
- Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes).
- Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
- Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution.
- a lyophilized formulation 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized.
- the infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.
- the invention also provides a pharmaceutical pack or kit comprising one or more containers fiUed with one or more of the ingredients of the pharmaceutical compositions of the invention.
- a pharmaceutical pack or kit comprising one or more containers fiUed with one or more of the ingredients of the pharmaceutical compositions of the invention.
- Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.
- Example 24 Method of Treating Decreased Levels of the Polypeptide
- the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.
- a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days.
- the polypeptide is in the secreted form.
- the exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.
- Example 25 Method of Treating Increased Levels of the Polypeptide Antisense technology is used to inhibit production of a polypeptide of the present invention.
- This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.
- a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated.
- the formulation of the antisense polynucleotide is provided in Example 23.
- Example 26 Method of Treatment Using Gene Therapy
- fibroblasts which are capable of expressing a polypeptide, onto a patient.
- fibroblasts are obtained from a subject by skin biopsy.
- the resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask.
- the flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added.
- fresh media e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin
- the flasks are then incubated at 37°C for approximately one week. At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.
- pMV-7 (Kirschmeier, P.T. et al, DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and Hindlll and subsequently treated with calf intestinal phosphatase.
- the linear vector is fractionated on agarose gel and purified, using glass beads.
- the cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which conespond to the 5' and 3' end sequences respectively as set forth in Example 1.
- the 5' primer contains an EcoRI site and the 3' primer includes a Hindlll site.
- Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and Hindlll fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments.
- the ligation mixture is then used to transform bacteria HB 101 , which are then plated onto agar containing kanamycin for the pu ⁇ ose of confirming that the vector has the gene of interest properly inserted.
- the amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin.
- DMEM Dulbecco's Modified Eagles Medium
- CS calf serum
- the MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector.
- the packaging cells now produce infectious viral particles containing the gene (the packaging cells are now refened to as producer cells).
- Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells.
- the spent media containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells.
- Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (39)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4835P | 1995-10-05 | ||
US4127697P | 1997-03-21 | 1997-03-21 | |
US4128197P | 1997-03-21 | 1997-03-21 | |
US4234497P | 1997-03-21 | 1997-03-21 | |
US4234P | 1997-03-21 | ||
US4127P | 1997-03-21 | ||
US4128P | 1997-03-21 | ||
US5093797P | 1997-05-30 | 1997-05-30 | |
US4835197P | 1997-05-30 | 1997-05-30 | |
US4809697P | 1997-05-30 | 1997-05-30 | |
US4818697P | 1997-05-30 | 1997-05-30 | |
US4835597P | 1997-05-30 | 1997-05-30 | |
US4818897P | 1997-05-30 | 1997-05-30 | |
US4809497P | 1997-05-30 | 1997-05-30 | |
US4815497P | 1997-05-30 | 1997-05-30 | |
US4835097P | 1997-05-30 | 1997-05-30 | |
US4813197P | 1997-05-30 | 1997-05-30 | |
US4809597P | 1997-05-30 | 1997-05-30 | |
US4835297P | 1997-05-30 | 1997-05-30 | |
US4809997P | 1997-05-30 | 1997-05-30 | |
US4813597P | 1997-05-30 | 1997-05-30 | |
US4818797P | 1997-05-30 | 1997-05-30 | |
US4816097P | 1997-05-30 | 1997-05-30 | |
US4806997P | 1997-05-30 | 1997-05-30 | |
US4815P | 1997-05-30 | ||
US5093P | 1997-05-30 | ||
US4813P | 1997-05-30 | ||
US4809P | 1997-05-30 | ||
US48350P | 1997-05-30 | ||
US4816P | 1997-05-30 | ||
US4818P | 1997-05-30 | ||
US4806P | 1997-05-30 | ||
US5480497P | 1997-08-05 | 1997-08-05 | |
US54804P | 1997-08-05 | ||
US5637097P | 1997-08-19 | 1997-08-19 | |
US56370P | 1997-08-19 | ||
US6086297P | 1997-10-02 | 1997-10-02 | |
US60862P | 1997-10-02 | ||
PCT/US1998/005311 WO1998042738A1 (en) | 1997-03-21 | 1998-03-19 | 87 human secreted proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0970110A1 true EP0970110A1 (de) | 2000-01-12 |
Family
ID=27586692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98911772A Withdrawn EP0970110A1 (de) | 1997-03-21 | 1998-03-19 | 87 humane sekretierte proteine |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP0970110A1 (de) |
-
1998
- 1998-03-19 EP EP98911772A patent/EP0970110A1/de not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9842738A1 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030069406A1 (en) | 87 human secreted proteins | |
WO1998042738A9 (en) | 87 human secreted proteins | |
US7105644B2 (en) | Secreted protein HHTLF25 antibodies | |
US6569992B1 (en) | Protein HLQDR48 | |
US6420526B1 (en) | 186 human secreted proteins | |
WO1998039448A9 (en) | 186 human secreted proteins | |
EP1039801A1 (de) | 207 menschliche sekretierte proteine | |
US6531447B1 (en) | Secreted protein HEMCM42 | |
EP1040117A1 (de) | 110 menschliche sekretierte proteines | |
US6525174B1 (en) | Precerebellin-like protein | |
US20030045459A1 (en) | 67 Human secreted proteins | |
WO1998056804A1 (en) | 86 human secreted proteins | |
EP1005544A1 (de) | 70 menschliche, sekretierte proteine | |
CA2296815A1 (en) | 64 human secreted proteins | |
US20030105297A1 (en) | Secreted protein HEMCM42 | |
US6806351B2 (en) | Secreted protein HBJFE12 | |
US20040157258A1 (en) | 101 human secreted proteins | |
EP0970110A1 (de) | 87 humane sekretierte proteine | |
US20020058307A1 (en) | 20 Human secreted proteins | |
EP1042346A1 (de) | 86 menschliche sekretierte proteine | |
EP0972030A2 (de) | 70 humane sekretierte proteine | |
US20030211472A1 (en) | 125 human secreted proteins | |
EP1445316A1 (de) | Neues sekretiertes Protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19991021 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20041005 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060110 |